Endocrinology and Metabolism

Original Articles

Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis: A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Deep Dutta, Thanikai Sasikanth, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra; Received September 29, 2024 Accepted November 14, 2024 Published online January 15, 2025; DOI: https://doi.org/10.3803/EnM.2024.2164 [Epub ahead of print]

1,343 View
128 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Data on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess the cancer risk associated with tirzepatide.
Methods
RCTs involving patients receiving tirzepatide in the intervention arm and either a placebo or any active comparator in the control arm were searched through electronic databases. The primary outcome was the overall risk of any cancer, and secondary outcomes were the risks of specific types of cancer in the tirzepatide versus the control groups.
Results
Thirteen RCTs with 13,761 participants were analyzed. Over 26 to 72 weeks, the tirzepatide and pooled control groups had identical risks of any cancer (risk ratio, 0.78; 95% confidence interval, 0.53 to 1.16; P=0.22). The two groups had comparable cancer risks in patients with and without diabetes. In subgroup analyses, the risks were also similar in the tirzepatide versus placebo, insulin, and glucagon-like peptide-1 receptor agonist groups. The overall cancer risk was also comparable for different doses of tirzepatide compared to the control groups; only a 10-mg tirzepatide dose had a lower risk of any cancer than placebo. Furthermore, compared to the control groups (pooled or separately), tirzepatide did not increase the risk of any specific cancer types. Despite greater increments in serum calcitonin with 10- and 15-mg tirzepatide doses than with placebo, the included RCTs reported no cases of papillary thyroid carcinoma.
Conclusion
Tirzepatide use in RCTs over 26 to 72 weeks did not increase overall or specific cancer risk.

Effectiveness and Safety of Oral Quadruple Combination Therapy in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis: Jaehyun Bae, Min Heui Yu, Minyoung Lee, Bong-Soo Cha, Byung-Wan Lee; Received July 29, 2024 Accepted November 5, 2024 Published online January 13, 2025; DOI: https://doi.org/10.3803/EnM.2024.2120 [Epub ahead of print]

306 View
24 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Achieving optimal glucose control is essential in the management of type 2 diabetes (T2D). This study aimed to evaluate the effectiveness and safety of oral quadruple combination therapy for the treatment of T2D.
Methods
This meta-analysis reviewed original research on oral quadruple combination therapy for T2D, including both experimental and observational studies with a minimum duration of 12 weeks. The primary endpoint was the change in glycated hemoglobin (HbA1c) from baseline to follow-up. The secondary endpoint was the incidence rate of adverse events. Two investigators independently extracted data and assessed the risk of bias. Outcomes were pooled as the standardized mean difference (using Hedge’s g) and the risk ratio for adverse events in random-effects meta-analyses.
Results
The meta-analysis included 17 studies. Oral quadruple combination therapy resulted in an additional mean reduction in HbA1c levels of 1.1% in patients who did not achieve glycemic control with oral triple combination therapy. Compared with switching to injectables, such as insulin or a glucagon-like peptide-1 receptor agonist–containing regimen, this therapy was non-inferior, even demonstrating a slightly superior glucose-lowering effect. Furthermore, it was determined to be safe, with an adverse event rate of 0.25, indicating no significant difference in safety compared with adding a placebo or switching to an injectable-containing regimen.
Conclusion
Oral quadruple combination therapy is a valid option for patients with T2D who are unable to achieve glycemic targets with oral triple combination therapy, offering both effective glycemic control and a favorable safety profile.

Thyroid
Prognosis of Poorly Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis: Ji Young Kim, Jae Kyung Myung, Soyun Kim, Kyung Tae, Yun Young Choi, Soo Jin Lee; Endocrinol Metab. 2024;39(4):590-602. Published online June 27, 2024; DOI: https://doi.org/10.3803/EnM.2024.1927

3,568 View
153 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Poorly differentiated thyroid carcinoma (PDTC) accounts for a small portion of thyroid carcinomas but contributes to a significant proportion of thyroid carcinoma-associated deaths. The clinicopathological prognostic factors and clinical outcomes of PDTC remain unclear. We aimed to evaluate the clinical outcomes of patients with PDTC after curative treatment.
Methods
A comprehensive search was performed up to September 2023. We included studies investigating treatment outcomes in patients with PDTC who underwent initial surgery. The 5-year disease-free survival (DFS) and overall survival (OS) were extracted. In this meta-analysis, the enrolled PDTC histological criteria included 3rd, 4th, and 5th World Health Organization (WHO) and Memorial Sloan Kettering Cancer Center (MSKCC) classification. A random-effects model was used for the pooled proportion analysis. Meta-regression analysis was conducted to evaluate the prognostic factors.
Results
Twenty retrospective studies published between 2007 and 2023, including 1,294 patients, met all inclusion criteria. Studies that diagnosed PDTC based on various histological criteria including 3rd WHO (n=5), 4th WHO (n=12), 5th WHO (n=2), and MSKCC (n=1) were included. Overall, 5-year DFS and 5-year OS were 49.4% (95% confidence interval [CI], 42.3 to 56.4) and 73.8% (95% CI, 66.5 to 79.9), with moderate heterogeneity of 58% and 55%, respectively. In meta-regression analysis, extrathyroidal extension (ETE) was a prognostic factor for OS.
Conclusion
The meta-analysis of DFS and OS in patients with PDTC show the moderate heterogeneity with a variety of histological criteria. ETE appears to have a significant impact on OS, regardless of histological criteria.

Citations

Citations to this article as recorded by

Aggressive Types of Malignant Thyroid Neoplasms
Maria Boudina, Eleana Zisimopoulou, Persefoni Xirou, Alexandra Chrisoulidou
Journal of Clinical Medicine.2024; 13(20): 6119. CrossRef

Diabetes, obesity and metabolism
Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis: A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Deep Dutta, Shahjada Selim; Endocrinol Metab. 2024;39(1):109-126. Published online January 23, 2024; DOI: https://doi.org/10.3803/EnM.2023.1839

3,197 View
110 Download
7 Web of Science
11 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
No recent meta-analysis has holistically analyzed and summarized the efficacy and safety of omarigliptin in type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to address this knowledge gap.
Methods
Electronic databases were searched to identify randomized controlled trials (RCTs) that included patients with T2DM who received omarigliptin in the intervention arm. The control arm consisted of either a placebo (passive control group [PCG]) or an active comparator (active control group [ACG]). The primary outcome assessed was changes in hemoglobin A1c (HbA1c), while secondary outcomes included variations in glucose levels, achievement of glycemic targets, adverse events (AEs), and hypoglycemic events.
Results
From 332 initially screened articles, data from 16 RCTs involving 8,804 subjects were analyzed. Omarigliptin demonstrated superiority over placebo in reducing HbA1c levels (mean difference, –0.58%; 95% confidence interval, –0.75 to –0.40; P<0.00001; I²=91%). Additionally, omarigliptin outperformed placebo in lowering fasting plasma glucose, 2-hour postprandial glucose, and in the percentage of participants achieving HbA1c levels below 7.0% and 6.5%. The glycemic efficacy of omarigliptin was similar to that of the ACG across all measures. Although the omarigliptin group experienced a higher incidence of hypoglycemic events compared to the PCG, the overall AEs, serious AEs, hypoglycemia, and severe hypoglycemia were comparable between the omarigliptin and control groups (PCG and ACG).
Conclusion
Omarigliptin has a favorable glycemic efficacy and safety profile for managing T2DM.

Citations

Citations to this article as recorded by

Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis
A B M Kamrul-Hasan, Shinjan Patra, Deep Dutta, Lakshmi Nagendra, AFM Muntahi-Reza, Sanja Borozan, Joseph M Pappachan
World Journal of Diabetes.2025;[Epub] CrossRef
Role of flibanserin in managing hypoactive sexual desire disorder in women: A systematic review and meta-analysis
A.B.M. Kamrul-Hasan, Mohammad Abdul Hannan, Muhammad Shah Alam, Fatema Tuz Zahura Aalpona, Lakshmi Nagendra, Shahjada Selim, Deep Dutta
Medicine.2024; 103(25): e38592. CrossRef
Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy
Ashraf Al Madhoun
World Journal of Diabetes.2024; 15(8): 1654. CrossRef
Inhibition of Oxidative Stress and Related Signaling Pathways in Neuroprotection
Maja Jazvinšćak Jembrek
Antioxidants.2024; 13(9): 1033. CrossRef
Safety and Efficacy of the Novel RNA Interference Therapies for Hypertriglyceridemia and Mixed Hyperlipidemia Management: A Systematic Review and Meta-analysis
A.B.M. Kamrul-Hasan, Deep Dutta, Lakshmi Nagendra, Sunetra Mondal, Saptarshi Bhattacharya, Sanjay Kalra
Endocrine Practice.2024; 30(11): 1103. CrossRef
Hepatobiliary effects and safety of tirzepatide: A systematic review and meta‐analysis
A. B. M. Kamrul‐Hasan, Deep Dutta, Lakshmi Nagendra, Mohammad Shafi Kuchay, Md. Saiful Islam, Joseph M. Pappachan
Diabetes, Obesity and Metabolism.2024; 26(12): 6074. CrossRef
Efficacy and Safety of Ertugliflozin Compared to Placebo in Patients With Type 2 Diabetes: An Updated Systematic Review and Meta‐Analysis
A. B. M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Mohammad Abdul Hannan, Deep Dutta, Lakshmi Nagendra, Shahjada Selim, Eusebio Chiefari
Journal of Diabetes Research.2024;[Epub] CrossRef
Once-Weekly Tirzepatide Versus Once-Daily Basal Insulin in Managing Type 2 Diabetes Inadequately Controlled With Oral anti-Hyperglycemic Drugs: A Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Shahjada Selim, Faria Afsana, Lakshmi Nagendra, Rezwana Ahmed, Deep Dutta
Endocrine Practice.2024;[Epub] CrossRef
Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Manoj Kumar, A.B.M. Kamrul-Hasan, Saptarshi Bhattacharya
Endocrine Practice.2024;[Epub] CrossRef
Neuropsychiatric Effects of Tirzepatide: A Systematic Review and Meta-Analysis
A.B.M. Kamrul-Hasan, Sanja Borozan, Deep Dutta, Lakshmi Nagendra, Dina Shrestha, Joseph M. Pappachan
Endocrine Practice.2024;[Epub] CrossRef
Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis
A. B. M. Kamrul‐Hasan, Sunetra Mondal, Deep Dutta, Lakshmi Nagendra, Mohammed Ruhul Kabir, Joseph M. Pappachan
Obesity Science & Practice.2024;[Epub] CrossRef

Diabetes, obesity and metabolism
Association between Serum Amyloid A Levels and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis: Ting Liu, Meng Li, Chunying Cui, Jielin Zhou; Endocrinol Metab. 2023;38(3):315-327. Published online June 7, 2023; DOI: https://doi.org/10.3803/EnM.2023.1621

4,013 View
132 Download
3 Web of Science
4 Crossref

Abstract PDF PubReader ePub

Background
To date, consistent data have not been reported on the association between serum amyloid A (SAA) levels and type 2 diabetes mellitus (T2DM). The purpose of this study was to systematically summarize their relationship.
Methods
Databases including PubMed, Cochrane Library, Embase, Web of Science, and MEDLINE were searched until August 2021. Cross-sectional and case-control studies were included.
Results
Twenty-one studies with 1,780 cases and 2,070 controls were identified. SAA levels were significantly higher in T2DM patients than in healthy groups (standardized mean difference [SMD], 0.68; 95% confidence interval [CI], 0.39 to 0.98). A subgroup analysis showed that the mean age of participants and the continent that participants were from were related to differences in SAA levels between cases and controls. Furthermore, in T2DM patients, SAA levels were positively associated with body mass index (r=0.34; 95% CI, 0.03 to 0.66), triglycerides (r=0.12; 95% CI, 0.01 to 0.24), fasting plasma glucose (r=0.26; 95% CI, 0.07 to 0.45), hemoglobin A1c (r=0.24; 95% CI, 0.16 to 0.33), homeostasis model assessment for insulin resistance (r=0.22; 95% CI, 0.10 to 0.34), C-reactive protein (r=0.77; 95% CI, 0.62 to 0.91), and interleukin-6 (r=0.42; 95% CI, 0.31 to 0.54), but negatively linked with highdensity lipoprotein cholesterol (r=–0.23; 95% CI, –0.44 to –0.03).
Conclusion
The meta-analysis suggests that high SAA levels may be associated with the presence of T2DM, as well as lipid metabolism homeostasis and the inflammatory response.

Citations

Citations to this article as recorded by

Recent Advances in Studies of Serum Amyloid A: Implications in Inflammation, Immunity and Tumor Metastasis
Yixin Chang, Yezhou Liu, Yuanrui Zou, Richard D. Ye
International Journal of Molecular Sciences.2025; 26(3): 987. CrossRef
Correlation between insulin resistance and the rate of neutrophils-lymphocytes, monocytes-lymphocytes, platelets-lymphocytes in type 2 diabetic patients
Yuanyuan Zhang, Huaizhen Liu
BMC Endocrine Disorders.2024;[Epub] CrossRef
Integrated Network-Based Analysis of Diseases Associated with Amyloid Deposition Through a Disease–Protein–Drug Network
Aikaterini E. I. Rizou, Georgia I. Nasi, Avgi E. Apostolakou, Meletios A. Dimopoulos, Efstathios Kastritis, Vassiliki A. Iconomidou
Pharmaceuticals.2024; 17(12): 1736. CrossRef
Antioxidant and Anti-Inflammatory Functions of High-Density Lipoprotein in Type 1 and Type 2 Diabetes
Damien Denimal
Antioxidants.2023; 13(1): 57. CrossRef

Thyroid Thyroid Cancer Screening
Diagnostic Performance of Ultrasound-Based Risk Stratification Systems for Thyroid Nodules: A Systematic Review and Meta-Analysis: Leehi Joo, Min Kyoung Lee, Ji Ye Lee, Eun Ju Ha, Dong Gyu Na; Endocrinol Metab. 2023;38(1):117-128. Published online February 27, 2023; DOI: https://doi.org/10.3803/EnM.2023.1670

3,801 View
200 Download
6 Web of Science
10 Crossref

Abstract PDF PubReader ePub

Background
This study investigated the diagnostic performance of biopsy criteria in four society ultrasonography risk stratification systems (RSSs) for thyroid nodules, including the 2021 Korean (K)-Thyroid Imaging Reporting and Data System (TIRADS).
Methods
The Ovid-MEDLINE, Embase, Cochrane, and KoreaMed databases were searched and a manual search was conducted to identify original articles investigating the diagnostic performance of biopsy criteria for thyroid nodules (≥1 cm) in four widely used society RSSs.
Results
Eleven articles were included. The pooled sensitivity and specificity were 82% (95% confidence interval [CI], 74% to 87%) and 60% (95% CI, 52% to 67%) for the American College of Radiology (ACR)-TIRADS, 89% (95% CI, 85% to 93%) and 34% (95% CI, 26% to 42%) for the American Thyroid Association (ATA) system, 88% (95% CI, 81% to 92%) and 42% (95% CI, 22% to 67%) for the European (EU)-TIRADS, and 96% (95% CI, 94% to 97%) and 21% (95% CI, 17% to 25%) for the 2016 K-TIRADS. The sensitivity and specificity were 76% (95% CI, 74% to 79%) and 50% (95% CI, 49% to 52%) for the 2021 K-TIRADS_1.5 (1.5-cm size cut-off for intermediate-suspicion nodules). The pooled unnecessary biopsy rates of the ACR-TIRADS, ATA system, EU-TIRADS, and 2016 K-TIRADS were 41% (95% CI, 32% to 49%), 65% (95% CI, 56% to 74%), 68% (95% CI, 60% to 75%), and 79% (95% CI, 74% to 83%), respectively. The unnecessary biopsy rate was 50% (95% CI, 47% to 53%) for the 2021 K-TIRADS_1.5.
Conclusion
The unnecessary biopsy rate of the 2021 K-TIRADS_1.5 was substantially lower than that of the 2016 K-TIRADS and comparable to that of the ACR-TIRADS. The 2021 K-TIRADS may help reduce potential harm due to unnecessary biopsies.

Citations

Citations to this article as recorded by

Accuracy of ultrasound in predicting thyroid malignancy: a comparative analysis of the ACR TI-RADS and ATA risk stratification systems
Shaza Samargandy, Aliaa H. Ghoneim
Archives of Endocrinology and Metabolism.2024;[Epub] CrossRef
Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules 2024
Young Joo Park, Eun Kyung Lee, Young Shin Song, Su Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung,
International Journal of Thyroidology.2024; 17(1): 208. CrossRef
Individual Ultrasonographic Characteristics of Thyroid Nodules and Their Cytopathological Correlation to Determine Malignancy Risk
Miguel Ángel Castilla Villanueva, Dania Guadalupe Solis Cano, Ana Amador Martínez, Marco Antonio Téliz Meneses, Jesús Baquera-Heredia, Cesar Eduardo Vallin Orozco, Mónica Loya Ceballos
Cureus.2024;[Epub] CrossRef
Improving the diagnostic performance of inexperienced readers for thyroid nodules through digital self-learning and artificial intelligence assistance
Si Eun Lee, Hye Jung Kim, Hae Kyoung Jung, Jin Hyang Jung, Jae-Han Jeon, Jin Hee Lee, Hanpyo Hong, Eun Jung Lee, Daham Kim, Jin Young Kwak
Frontiers in Endocrinology.2024;[Epub] CrossRef
Systemic therapy for differentiated thyroid cancer with distant metastasis
Eun Kyung Lee
Journal of the Korean Medical Association.2024; 67(7): 484. CrossRef
To Screen or Not to Screen?
Do Joon Park
Endocrinology and Metabolism.2023; 38(1): 69. CrossRef
The 2017 United States Preventive Services Task Force Recommendation for Thyroid Cancer Screening Is No Longer the Gold Standard
Ka Hee Yi
Endocrinology and Metabolism.2023; 38(1): 72. CrossRef
Thyroid Cancer Screening: How to Maximize Its Benefits and Minimize Its Harms
Jung Hwan Baek
Endocrinology and Metabolism.2023; 38(1): 75. CrossRef
2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules
Young Joo Park, Eun Kyung Lee, Young Shin Song, Soo Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung
International Journal of Thyroidology.2023; 16(1): 1. CrossRef
Evaluation of the Appropriateness of Thyroid Fine-Needle Aspiration
Lairce Cristina Ribeiro Brito, Iara Beatriz De Carvalho Botêlho, Lanna Matos Silva Fernandes, Nayze Lucena Sangreman Aldeman, Uziel Nunes Silva
International Journal for Innovation Education and Research.2023; 11(6): 8. CrossRef

Calcium & Bone Metabolism
Effect of Vitamin D Supplementation on Risk of Fractures and Falls According to Dosage and Interval: A Meta-Analysis: Sung Hye Kong, Han Na Jang, Jung Hee Kim, Sang Wan Kim, Chan Soo Shin; Endocrinol Metab. 2022;37(2):344-358. Published online April 25, 2022; DOI: https://doi.org/10.3803/EnM.2021.1374

10,424 View
384 Download
25 Web of Science
26 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Although recent studies comparing various dosages and intervals of vitamin D supplementation have been published, it is yet to be elucidated whether there is an appropriate dose or interval to provide benefit regarding fracture risk. We aimed to assess the published evidence available to date regarding the putative beneficial effects of vitamin D supplements on fractures and falls according to various dosages and intervals.
Methods
We performed a meta-analysis of randomized controlled studies reporting associations between vitamin D supplementation and the risks of fractures and falls in PubMed, EMBASE, and Cochrane library. Studies with supplements of ergocalciferol or calcitriol, those with a number of event ≤10, or those with a follow-up duration of less than 6 months were also excluded.
Results
Thirty-two studies were included in the final analysis. Vitamin D supplementation with daily dose of 800 to 1,000 mg was associated with lower risks of osteoporotic fracture and fall (pooled relative risk [RR], 0.87; 95% confidence interval [CI], 0.78 to 0.97 and RR, 0.91; 95% CI, 0.85 to 0.98), while studies with <800 or >1,000 mg/day did not. Also, among intervals, daily administration of vitamin D was associated with the reduced risk of falls, while intermittent dose was not. Also, patients with vitamin D deficiency showed a significant risk reduction of falls after vitamin D supplementation.
Conclusion
Daily vitamin D dose of 800 to 1,000 IU was the most probable way to reduce the fracture and fall risk. Further studies designed with various regimens and targeted vitamin D levels are required to elucidate the benefits of vitamin D supplements.

Citations

Citations to this article as recorded by

Ukrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults
Nataliia Grygorieva, Mykola Tronko, Volodymir Kovalenko, Serhiy Komisarenko, Tetiana Tatarchuk, Ninel Dedukh, Mykola Veliky, Serhiy Strafun, Yulia Komisarenko, Andrii Kalashnikov, Valeria Orlenko, Volodymyr Pankiv, Oleg Shvets, Inna Gogunska, Svitlana Reg
Nutrients.2024; 16(2): 270. CrossRef
Vitamin D Supplementation: A Review of the Evidence Arguing for a Daily Dose of 2000 International Units (50 µg) of Vitamin D for Adults in the General Population
Pawel Pludowski, William B. Grant, Spyridon N. Karras, Armin Zittermann, Stefan Pilz
Nutrients.2024; 16(3): 391. CrossRef
Clinical Characteristics and Outcomes of Limb Fractures in Saudi Children
Lamia Aldhbiban, Fai Alhoshan, Raghad Alomari, Shahad A Almatrafi, Yousef Alanazi, Samir Alsayegh, Haifa Y Alfaraidi, Ayman H Jawadi, Fahad N Aljuraibah
Cureus.2024;[Epub] CrossRef
The interplay of rheumatoid arthritis and osteoporosis: exploring the pathogenesis and pharmacological approaches
Nikhil Gupta, Navjot Kanwar, Anchal Arora, Kavin Khatri, Abhinav Kanwal
Clinical Rheumatology.2024; 43(5): 1421. CrossRef
The multi-faceted nature of age-associated osteoporosis
A.E. Smit, O.C. Meijer, E.M. Winter
Bone Reports.2024; 20: 101750. CrossRef
Vitamin D Deficiency in Patients With Low-Energy Hip Fractures in Accordance With the Mediterranean Paradox
Christos Konstantinidis, Ourania Psoma, Christos Kotsias, Vasileios Panagiotopoulos , Sotiris Plakoutsis, Dimitrios Tsiampas, Dimitrios Vardakas, Dimitrios Giotis
Cureus.2024;[Epub] CrossRef
Effect of vitamin D, calcium, or combined supplementation on fall prevention: a systematic review and updated network meta-analysis
Long Tan, Ruiqian He, Xiaoxue Zheng
BMC Geriatrics.2024;[Epub] CrossRef
Analysis of medication treatment for women with osteoporosis: A real-world retrospective study from Chinese tertiary grade A hospital
Xiaolei Liu, Zhenling Zhu, Xianli Wang
Bone Reports.2024; 21: 101778. CrossRef
New insights into dairy management and the prevention and treatment of osteoporosis: The shift from single nutrient to dairy matrix effects—A review
Kaili Wang, Xu Zhao, Sijia Yang, Xiaoxi Qi, Aili Li, Wei Yu
Comprehensive Reviews in Food Science and Food Safety.2024;[Epub] CrossRef
The Importance of Vitamin K and the Combination of Vitamins K and D for Calcium Metabolism and Bone Health: A Review
Jan O. Aaseth, Trine Elisabeth Finnes, Merete Askim, Jan Alexander
Nutrients.2024; 16(15): 2420. CrossRef
The role of anti-osteoporosis drugs in fall risk
Gianpaolo Voltan, Nicola Veronese
International Journal of Bone Fragility.2024; 4(1): 2. CrossRef
Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease
Amy Y. Sato, Meloney Cregor, Kevin McAndrews, Charles A. Schurman, Eric Schaible, Jennifer Shutter, Punit Vyas, Bhawana Adhikari, Monte S. Willis, Marjan Boerma, Tamara Alliston, Teresita Bellido
JCI Insight.2024;[Epub] CrossRef
Vitamin D levels and bone mineral density: a prospective cross-sectional analysis of young orthopedic trauma patients at a rural United States trauma center
Michael Booth, Kenneth Sabacinski, Colleen Watkins, Erin Butcho, Emilie Kramer, Lukas Meadows, Michelle A. Bramer
Journal of Trauma and Injury.2024; 37(4): 276. CrossRef
Association of vitamin and/or nutritional supplements with fall among patients with diabetes: A prospective study based on ACCORD and UK Biobank
Lingfang He, Tianqi Ma, Guogang Zhang, Xunjie Cheng, Yongping Bai
Frontiers in Nutrition.2023;[Epub] CrossRef
Vitamin D and Calcium in Osteoporosis, and the Role of Bone Turnover Markers: A Narrative Review of Recent Data from RCTs
Gavriela Voulgaridou, Sousana K. Papadopoulou, Paraskevi Detopoulou, Despoina Tsoumana, Constantinos Giaginis, Foivi S. Kondyli, Evgenia Lymperaki, Agathi Pritsa
Diseases.2023; 11(1): 29. CrossRef
Recent advances in the identification of related factors and preventive strategies of hip fracture
Yaohui Yu, Yudan Wang, Xiaoli Hou, Faming Tian
Frontiers in Public Health.2023;[Epub] CrossRef
Can Nutrition Contribute to a Reduction in Sarcopenia, Frailty, and Comorbidities in a Super-Aged Society?
Sadao Yoshida, Ryo Shiraishi, Yuki Nakayama, Yasuko Taira
Nutrients.2023; 15(13): 2991. CrossRef
Safety Profile of Vitamin D in Italy: An Analysis of Spontaneous Reports of Adverse Reactions Related to Drugs and Food Supplements
Valentina Maggini, Giada Crescioli, Ilaria Ippoliti, Eugenia Gallo, Francesca Menniti-Ippolito, Adelaide Chiaravalloti, Vittorio Mascherini, Roberto Da Cas, Simona Potenza, Giulia Gritti, Maria Galiulo, Laura Sottosanti, Alfredo Vannacci, Niccolò Lombardi
Journal of Clinical Medicine.2023; 12(14): 4726. CrossRef
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly
Sabrina Chiloiro, Stefano Frara, Irene Gagliardi, Antonio Bianchi, Antonella Giampietro, Margherita Medici, Agnese Allora, Luigi di Filippo, Maria Rosaria Ambrosio, Alfredo Pontecorvi, Maria Chiara Zatelli, Laura De Marinis, Andrea Giustina
The Journal of Clinical Endocrinology & Metabolism.2023; 109(1): e58. CrossRef
Proceedings of the 2023 Santa Fe Bone Symposium: Progress and Controversies in the Management of Patients with Skeletal Diseases
E. Michael Lewiecki, Teresita Bellido, John P. Bilezikian, Jacques P. Brown, Azeez Farooki, Christopher S. Kovacs, Brendan Lee, William D. Leslie, Michael R. McClung, Mark L. Prasarn, Deborah E. Sellmeyer
Journal of Clinical Densitometry.2023; 26(4): 101432. CrossRef
Diagnosis, prevention and treatment of vitamin D deficiency in adults: Ukrainian experts consensus statement
N.V. Grygorieva, M.D. Tronko, V.M. Kovalenko, S.V. Komisarenko, T.F. Tatarchuk, N.V. Dedukh, M.M. Veliky, S.S. Strafun, Y.I. Komisarenko, A.V. Kalashnikov, V.L. Orlenko, V.I. Pankiv, O.V. Shvets, I.V. Gogunska, S.I. Regeda
PAIN, JOINTS, SPINE.2023; 13(2): 60. CrossRef
Serum 25-Hydroxyvitamin D Level Is Negatively Associated with Fatigue in Elderly Maintenance Hemodialysis Patients
Menglin Pang, Lin Chen, Na Jiang, Mengmeng Jiang, Baofeng Wang, Lili Wang, Xiao-yan Jia
Kidney and Blood Pressure Research.2023; 48(1): 231. CrossRef
Vitamin D for Clinical Diseases in Women: An Indispensable Factor in Medicine and Dentistry
Dario Calafiore, Leonzio Fortunato, Mario Migliario
Journal of Clinical Medicine.2022; 11(11): 3104. CrossRef
Malnutrition in Older Adults—Effect on Falls and Fractures: A Narrative Review
Malgorzata Kupisz-Urbanska, Ewa Marcinowska-Suchowierska
Nutrients.2022; 14(15): 3123. CrossRef
Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group
Thierry Chevalley, Maria Luisa Brandi, Kevin D. Cashman, Etienne Cavalier, Nicholas C. Harvey, Stefania Maggi, Cyrus Cooper, Nasser Al-Daghri, Oliver Bock, Olivier Bruyère, Mario Miguel Rosa, Bernard Cortet, Alfonso J. Cruz-Jentoft, Antonio Cherubini, Bes
Aging Clinical and Experimental Research.2022; 34(11): 2603. CrossRef
The Relationship of Osteoporosis with Menopause: Review of Article
Hadeel Anwar Alsarraje, *Liqaa Khalel Alhyali
International Journal of Research in Medical Sciences and Technology.2022; 14(01): 127. CrossRef

Diabetes, Obesity and Metabolism
Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials: Shinje Moon, Jibeom Lee, Hye Soo Chung, Yoon Jung Kim, Jae Myung Yu, Sung Hoon Yu, Chang-Myung Oh; Endocrinol Metab. 2021;36(3):647-660. Published online June 18, 2021; DOI: https://doi.org/10.3803/EnM.2020.934

7,949 View
326 Download
18 Web of Science
19 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight and obese people. This study aimed to systematically analyze the effects of liraglutide on body weight and other cardiometabolic parameters.
Methods
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Results
We included 31 studies with 8,060 participants for this meta-analysis. The mean difference (MD) between the liraglutide group and the placebo group was −4.19 kg (95% confidence interval [CI], −4.84 to −3.55), with a −4.16% change from the baseline (95% CI, −4.90 to −3.43). Liraglutide treatment correlated with a significantly reduced body mass index (MD: −1.55; 95% CI, −1.76 to −1.34) and waist circumference (MD: −3.11 cm; 95% CI, −3.59 to −2.62) and significantly decreased blood pressure (systolic blood pressure, MD: −2.85 mm Hg; 95% CI, −3.36 to −2.35; diastolic blood pressure, MD: −0.66 mm Hg; 95% CI, −1.02 to −0.30), glycated hemoglobin (MD: −0.40%; 95% CI, −0.49 to −0.31), and low-density lipoprotein cholesterol (MD: –2.91 mg/dL; 95% CI, −5.28 to −0.53; MD: −0.87% change from baseline; 95% CI, −1.17 to −0.56).
Conclusion
Liraglutide is effective for weight control and can be a promising drug for cardiovascular protection in overweight and obese people.

Citations

Citations to this article as recorded by

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser
Translation: The University of Toledo Journal of Medical Sciences.2025;[Epub] CrossRef
Pharmacotherapy for obesity: moving towards efficacy improvement
Walmir Coutinho, Bruno Halpern
Diabetology & Metabolic Syndrome.2024;[Epub] CrossRef
Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic
Bruno Silvestrini, Mauro Silvestrini, Mayank Choubey
Journal of Obesity.2024; 2024: 1. CrossRef
Potent synergistic effects of dulaglutide and food restriction in prevention of olanzapine-induced metabolic adverse effects in a rodent model
Katerina Horska, Jan Kucera, Eva Drazanova, Gabriela Kuzminova, Petra Amchova, Maria Hrickova, Jana Ruda-Kucerova, Silje Skrede
Biomedicine & Pharmacotherapy.2024; 176: 116763. CrossRef
Association between weight loss and cardiovascular outcomes and mortality in Korea: A nationwide cohort study
So Yoon Kwon, Gyuri Kim, Seohyun Kim, Jae Hyeon Kim
Diabetes Research and Clinical Practice.2024; 214: 111767. CrossRef
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
De la découverte des hormones incrétines aux doubles et triples agonistes GIP / GLP-1 / glucagon
Franck Phan, Romane Bertrand, Chloé Amouyal, Fabrizio Andreelli
médecine/sciences.2024; 40(11): 837. CrossRef
Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
Yilin Li, Rong Lei, Honglin Lei, Qin Xiong, Fengjiao Xie, Chengjiao Yao, Peimin Feng
European Journal of Gastroenterology & Hepatology.2023; 35(1): 1. CrossRef
Recommendations for the prevention and management of obesity in the Iraqi population
Hussein Ali Nwayyir, Esraa Majid Mutasher, Osama Mohammed Alabid, Muthana Abdulrazzaq Jabbar, Wefak Hasan Abdulraheem Al-Kawaz, Haider Ayad Alidrisi, Majid Alabbood, Muhammed Chabek, Munib AlZubaidi, Lujain Anwar Al-khazrajy, Ibtihal Shukri Abd Alhaleem,
Postgraduate Medicine.2023; 135(5): 425. CrossRef
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, Rafik Karaman
Life.2023; 13(4): 1012. CrossRef
Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
Juyoung Shin, Raeun Kim, Hun-Sung Kim
Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 49. CrossRef
The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
Pejman Rohani, Nasser Malekpour Alamdari, Seyedeh Elaheh Bagheri, Azita Hekmatdoost, Mohammad Hassan Sohouli
Frontiers in Endocrinology.2023;[Epub] CrossRef
Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials
Hao Gou, Yiman Zhai, Junjun Guo
European Journal of Pediatrics.2023; 182(11): 5095. CrossRef
Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
Ping Zhong, Hai Zeng, Miaochun Huang, Wenbin Fu, Zhixia Chen
Endocrine.2022; 75(3): 718. CrossRef
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
David C. W. Lau, Rachel L Batterham, Carel W. le Roux
Expert Review of Clinical Pharmacology.2022; 15(3): 251. CrossRef
Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine
Peter Manu, Cristina-Mihaela Lăcătuşu, Liliana M. Rogozea, Simona Cernea
American Journal of Therapeutics.2022; 29(4): e410. CrossRef
GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
Katerina Horska, Jana Ruda-Kucerova, Silje Skrede
Trends in Endocrinology & Metabolism.2022; 33(9): 628. CrossRef
Targeting skeletal muscle mitochondrial health in obesity
Chantal A. Pileggi, Breana G. Hooks, Ruth McPherson, Robert R.M. Dent, Mary-Ellen Harper
Clinical Science.2022; 136(14): 1081. CrossRef
A Study on Weight Loss Cause as per the Side Effect of Liraglutide
Jin Yu, Jeongmin Lee, Seung-Hwan Lee, Jae-Hyung Cho, Hun-Sung Kim, Heng Zhou
Cardiovascular Therapeutics.2022; 2022: 1. CrossRef

Clinical Study
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis: Deep Dutta, Anshita Agarwal, Indira Maisnam, Rajiv Singla, Deepak Khandelwal, Meha Sharma; Endocrinol Metab. 2021;36(2):374-387. Published online April 6, 2021; DOI: https://doi.org/10.3803/EnM.2020.818

8,380 View
244 Download
23 Web of Science
34 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
No meta-analysis has holistically analysed and summarised the efficacy and safety of gemigliptin in type 2 diabetes. The meta-analysis addresses this knowledge gap.
Methods
Electronic databases were searched for randomised controlled trials (RCTs) involving diabetes patients receiving gemigliptin in the intervention arm and placebo/active comparator in the control arm. The primary outcome was change in haemoglobin A1c (HbA1c). The secondary outcomes were alterations in glucose, glycaemic targets, lipids, insulin resistance, and adverse events.
Results
Data from 10 RCTs involving 1,792 patients were analysed. Four had an active control group (ACG), with metformin/dapagliflozin/sitagliptin/glimepiride as the active comparator; six had a passive control group (PCG), with placebo/rosuvastatin as controls. HbA1c reduction by gemigliptin at 24 weeks was comparable to ACG (mean difference [MD], 0.09%; 95% confidence interval [CI], –0.06 to 0.23; P=0.24; I²=0%; moderate certainty of evidence [MCE]), but superior to PCG (MD, –0.91%; 95% CI, –1.18 to –0.63); P<0.01; I²=89%; high certainty of evidence [HCE]). Gemigliptin was superior to PCG regarding achieving HbA1c <7% (12 weeks: odds ratio [OR], 5.91; 95% CI, 1.34 to 26.08; P=0.02; I²=74%; 24 weeks: OR, 4.48; 95% CI, 2.09 to 9.60; P<0.01; I²=69%; HCE). Gemigliptin was comparable to ACG regarding achieving HbA1c <7% after 24 weeks (OR, 0.92; 95% CI, 0.52 to 1.63; P=0.77; I²=66%; MCE). Adverse events were similar between the gemigliptin and control groups (risk ratio [RR], 1.06; 95% CI, 0.82 to 1.36; P=0.66; I²=35%; HCE). The gemigliptin group did not have increased hypoglycaemia (RR, 1.19; 95% CI, 0.62 to 2.28; P=0.61; I²=19%; HCE).
Conclusion
Gemigliptin has good glycaemic efficacy and is well-tolerated over 6 months of use.

Citations

Citations to this article as recorded by

Efficacy and safety of the glucagon receptor antagonist volagidemab in type‐1 diabetes: A systematic review and meta‐analysis
Deep Dutta, A. B. M. Kamrul‐Hasan, Vineet Surana, Rajiv Singla, Deepak Khandelwal, Sameer Aggarwal, Lakshmi Nagendra, Saptarshi Bhattacharya
Annals of the New York Academy of Sciences.2025; 1543(1): 94. CrossRef
Efficacy and Safety of Tocilizumab in Polymyalgia Rheumatica: A Systematic Review and Meta‐Analysis
Meha Sharma, Siddharth Kumar Das, Ritin Mohindra, Deep Dutta
International Journal of Rheumatic Diseases.2025;[Epub] CrossRef
Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis
Lakshmi Nagendra, Deep Dutta, Sunetra Mondal, Nitin Kapoor, Ameya Joshi, Saptarshi Bhattacharya
Journal of Clinical Densitometry.2024; 27(1): 101453. CrossRef
Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis
Kunal Mahajan, Lakshmi Nagendra, Anil Dhall, Deep Dutta
European Journal of Internal Medicine.2024; 124: 99. CrossRef
Efficacy and safety of dorzagliatin, a novel glucokinase activators, in the treatment of T2DM: A meta-analysis of randomized controlled trials
Yuqian Wu, Kai Wang, Jingyang Su, Xin Liu
Medicine.2024; 103(8): e36916. CrossRef
Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis
Deep Dutta, Lakshmi Nagendra, Ameya Joshi, Suryashri Krishnasamy, Meha Sharma, Naresh Parajuli
Obesity Surgery.2024; 34(5): 1653. CrossRef
Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
Deep Dutta, Lakshmi Nagendra, Beatrice Anne, Manoj Kumar, Meha Sharma, A. B. M. Kamrul‐Hasan
Obesity Science & Practice.2024;[Epub] CrossRef
Safety and tolerability of sodium-glucose cotransporter-2 inhibitors in children and young adults: a systematic review and meta-analysis
Lakshmi Nagendra, Deep Dutta, Harish Bukkasagar Girijashankar, Deepak Khandelwal, Tejal Lathia, Meha Sharma
Annals of Pediatric Endocrinology & Metabolism.2024; 29(2): 82. CrossRef
Impact of Pheochromocytoma or Paraganglioma on Bone Metabolism: A Systemic Review and Meta-analysis
Deep Dutta, Lakshmi Nagendra, Manju Chandran, Meha Sharma, Saptarshi Bhattacharya, Satinath Mukhopadhyay
Journal of Clinical Densitometry.2024; 27(3): 101501. CrossRef
Long-Term Impact on Offspring (5 to 11 Years of Age) of Metformin Use in Pregnancy in Mothers With Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Meha Sharma, Lakshmi Nagendra, Saptarshi Bhattacharya, Ritin Mohindra, Chittaranjan S. Yajnik
Endocrine Practice.2024; 30(9): 854. CrossRef
Efficacy and Safety of Osilodrostat in Managing Cushing’s Syndrome: A Systematic Review and Meta-Analysis
Lakshmi Nagendra, Deep Dutta, Nishant Raizada, Vineet Surana, Chitra Selvan, Saptarshi Bhattacharya
Indian Journal of Endocrinology and Metabolism.2024; 28(3): 232. CrossRef
Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, BG Harish, Meha Sharma, Ameya Joshi, Basavanagowdappa Hathur, ABM Kamrul-Hasan
Indian Journal of Endocrinology and Metabolism.2024; 28(5): 436. CrossRef
Gender differences in the management and outcomes of acute coronary syndrome in indians: A systematic review and meta-analysis
Deep Dutta, Kunal Mahajan, Lokesh Verma, Gunjan Gupta, Meha Sharma
Indian Heart Journal.2024; 76(5): 333. CrossRef
Optimal Use of Once-Weekly Basal Insulin Efsitora Alfa in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Manoj Kumar, A.B.M. Kamrul-Hasan, Saptarshi Bhattacharya
Endocrine Practice.2024;[Epub] CrossRef
Efficacy and safety of novel dual glucokinase activator dorzagliatin in type-2 diabetes A meta-analysis
Deep Dutta, Deepak Khandelwal, Manoj Kumar, Meha Sharma
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102695. CrossRef
Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697. CrossRef
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study
Soo Lim, Minji Sohn, Jose C. Florez, Michael A. Nauck, Jiyoung Ahn
Nutrients.2023; 15(1): 248. CrossRef
Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy
Journal of Endocrinological Investigation.2023; 46(5): 855. CrossRef
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study
Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S
Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Verapamil improves One-Year C-Peptide Levels in Recent Onset Type-1 Diabetes: A Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Nishant Raizada, Saptarshi Bhattacharya, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(3): 192. CrossRef
Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis
Deep Dutta, B.G. Harish, Beatrice Anne, Lakshmi Nagendra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(8): 102816. CrossRef
Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, Harish BG, Meha Sharma, Deep Dutta
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(9): 102834. CrossRef
Efficacy and Safety of Novel Thiazolidinedione Rivoglitazone in Type-2 Diabetes a Meta-Analysis
Deep Dutta, Jyoti Kadian, Indira Maisnam, Ashok Kumar, Saptarshi Bhattacharya, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(4): 286. CrossRef
Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis
Lakshmi Nagendra, Kunal Mahajan, Gunjan Gupta, Deep Dutta
Indian Heart Journal.2023; 75(6): 416. CrossRef
Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials
Deep Dutta, Lakshmi Nagendra, Sowrabha Bhat, Ritin Mohindra, Vineet Surana, Anoop Misra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(10): 102877. CrossRef
Impact of Enhanced External Counter-pulsation Therapy on Glycaemic Control in People With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Lakshmi Nagendra, Deep Dutta, Meha Sharma, Harish Bg
touchREVIEWS in Endocrinology.2023; 19(2): 8. CrossRef
Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis
Deep Dutta, Subhankar Chatterjee, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(5): 377. CrossRef
Efficacy and Safety of Ultra-rapid Lispro Insulin in Managing Type-1 and Type-2 Diabetes: A Systematic Review and Meta-Analysis
Deep Dutta, Lakshmi Nagendra, Saptarshi Bhattacharya, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2023; 27(6): 467. CrossRef
Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis
Deep Dutta, Ritin Mohindra, Vineet Surana, Meha Sharma
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2022; 16(4): 102469. CrossRef
Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: A systematic review and meta-analysis
D Dutta, R Jindal, D Mehta, M Kumar, M Sharma
Journal of Postgraduate Medicine.2022; 68(2): 85. CrossRef
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung
Biochemical and Biophysical Research Communications.2022; 626: 135. CrossRef
Reporting and methodological quality of systematic reviews of DPP-4 inhibitors for patients with type 2 diabetes mellitus: an evidence-based mapping
Zouxi Du, Tingting Lu, Mingdong Gao, Limin Tian
Acta Diabetologica.2022; 59(12): 1539. CrossRef
Ranirestat Improves Electrophysiologic but not Clinical Measures of Diabetic Polyneuropathy
Deep Dutta, Ritin Mohindra, Manoj Kumar, Ashok Kumar, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2022; 26(5): 399. CrossRef
Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
Deep Dutta, Vineet Surana, Rajiv Singla, Sameer Aggarwal, Meha Sharma
Indian Journal of Endocrinology and Metabolism.2021; 25(6): 475. CrossRef

Clinical Study
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis: Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim; Endocrinol Metab. 2021;36(2):388-400. Published online March 31, 2021; DOI: https://doi.org/10.3803/EnM.2020.912

8,471 View
393 Download
14 Web of Science
17 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To compare the renal effects of dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors on individual outcomes in patients with type 2 diabetes.
Methods
We searched electronic databases (MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials) from inception to June 2019 to identity eligible randomized controlled trials of DPP-4 inhibitors or SGLT2 inhibitors that reported at least one kidney outcome in patients with type 2 diabetes. Outcomes of interest were microalbuminuria, macroalbuminuria, worsening nephropathy, and end-stage kidney disease (ESKD). We performed an arm-based network meta-analysis using Bayesian methods and calculated absolute risks and rank probabilities of each treatment for the outcomes.
Results
Seventeen studies with 87,263 patients were included. SGLT2 inhibitors significantly lowered the risks of individual kidney outcomes, including microalbuminuria (odds ratio [OR], 0.64; 95% credible interval [CrI], 0.41 to 0.93), macroalbuminuria (OR, 0.48; 95% CrI, 0.24 to 0.72), worsening nephropathy (OR, 0.65; 95% CrI, 0.44 to 0.91), and ESKD (OR, 0.65; 95% CrI, 0.46 to 0.98) as compared with placebo. However, DPP-4 inhibitors did not lower the risks. SGLT2 inhibitors were considerably associated with higher absolute risk reductions in all kidney outcomes than DPP-4 inhibitors, although the benefits were statistically insignificant. The rank probabilities showed that SGLT2 inhibitors were better treatments for lowering the risk of albuminuria and ESKD than placebo or DPP-4 inhibitors.
Conclusion
SGLT2 inhibitors were superior to DPP-4 inhibitors in reducing the risk of albuminuria and ESKD in patients with type 2 diabetes.

Citations

Citations to this article as recorded by

Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2024; 20(2): 212. CrossRef
Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study
Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa
Cardiovascular Diabetology.2024;[Epub] CrossRef
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Ji Soo Kim, Gyeongsil Lee, Kyung-Il Park, Seung-Won Oh
Diabetes & Metabolism Journal.2024; 48(2): 312. CrossRef
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Experimental and Clinical Endocrinology & Diabetes.2024; 132(07): 340. CrossRef
Clinical Management of Type II DM in patients Showing Progressive Increase in the Creatinine Level – A Cross-sectional Study
Prabhudatta Mohapatra, Durga Madhab Kar, Karmajeet Rath, Abhisek Pal
Research Journal of Pharmacy and Technology.2024; : 2719. CrossRef
Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2023; 19(5): 658. CrossRef
Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
Apichaya Chanawong, Suriyon Uitrakul, Supatcha Incomenoy, Natnicha Poonchuay, Rizky Abdulah
Advances in Pharmacological and Pharmaceutical Sciences.2023; 2023: 1. CrossRef
Different nursing interventions on sleep quality among critically ill patients: A systematic review and network meta-analysis
Daijin Huang, Yumei Li, Jing Ye, Chang Liu, Dongyan Shen, Yunhui Lv
Medicine.2023; 102(52): e36298. CrossRef
New trends in the approach to the treatment of type 2 diabetes - observations and benefits in the outpatient practice of a diabetologist
Pavel Weber, Hana Meluzínová, Dana Weberová
Klinická farmakologie a farmacie.2022; 35(4): 118. CrossRef
Comparative efficacy of novel antidiabetic drugs on cardiovascular and renal outcomes in patients with diabetic kidney disease: A systematic review and network meta‐analysis
Hongwei Cao, Tao Liu, Li Wang, Qiuhe Ji
Diabetes, Obesity and Metabolism.2022; 24(8): 1448. CrossRef
Therapie des Typ-2-Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Die Diabetologie.2022; 18(5): 623. CrossRef
Significant reduction in chronic kidney disease progression with sodium‐glucose cotransporter‐2 inhibitors compared to dipeptidyl peptidase‐4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on inte
Iskandar Idris, Ruiqi Zhang, Jil B. Mamza, Mike Ford, Tamsin Morris, Amitava Banerjee, Kamlesh Khunti
Diabetes, Obesity and Metabolism.2022; 24(11): 2138. CrossRef
Therapy of Type 2 Diabetes
Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel
Experimental and Clinical Endocrinology & Diabetes.2022; 130(S 01): S80. CrossRef
Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease
Kaixuan Zhou, Xue Zi, Jiayu Song, Qiulu Zhao, Jia Liu, Huiwei Bao, Lijing Li
Molecules.2022; 27(19): 6221. CrossRef
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Jiandong Zhou, Xuejin Liu, Oscar Hou-In Chou, Lifang Li, Sharen Lee, Wing Tak Wong, Qingpeng Zhang, Carlin Chang, Tong Liu, Gary Tse, Fengshi Jing, Bernard Man Yung Cheung
Rheumatology.2022;[Epub] CrossRef
New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
Chan-Hee Jung
Endocrinology and Metabolism.2021; 36(2): 339. CrossRef
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André J. Scheen
Diabetes & Metabolism.2021; 47(6): 101275. CrossRef

Clinical Study
Efficacy of Ethanol Ablation for Benign Thyroid Cysts and Predominantly Cystic Nodules: A Systematic Review and Meta-Analysis: Cheng-Chun Yang, Yung Hsu, Jyun-Yan Liou; Endocrinol Metab. 2021;36(1):81-95. Published online February 24, 2021; DOI: https://doi.org/10.3803/EnM.2020.833

7,691 View
266 Download
14 Web of Science
19 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Ultrasound-guided minimally invasive procedures are widely used to treat thyroid diseases. The objective of this study was to assess the efficacy and safety of ethanol ablation (EA) in comparison with other non-surgical options in the treatment of benign thyroid cystic nodules.
Methods
We conducted a systematic search of studies on EA for thyroid cystic nodules, mainly in the Ovid-MEDLINE and Embase, Web of Science, and Cochrane databases. The standardized mean difference (SMD) of the volume reduction ratio (VRR) after EA versus other non-surgical treatments comprised the primary outcome, whereas the odds ratio (OR) of therapeutic success rates between the two groups comprised the secondary outcome.
Results
The meta-analysis included 19 studies (four randomized controlled trials and 15 non-randomized studies) with 1,514 participants. The cumulative VRR of EA was 83.908% (95% confidence interval [CI], 79.358% to 88.457%). EA had a significantly higher pooled VRR (SMD, 0.381; 95% CI, 0.028 to 0.734; P=0.030), but not a significantly higher pooled therapeutic success rate (OR, 0.867; 95% CI, 0.132 to 5.689; P=0.880), than other forms of non-surgical management including radiofrequency ablation (RFA), polidocanol sclerotherapy, and simple aspiration with or without saline flush. However, the VRR and therapeutic success rate were not significantly different between EA and RFA. Major complications were recorded only in six patients (0.53%) with self-limiting dysphonia.
Conclusion
The role of EA as the first-line treatment for benign thyroid cysts and predominantly cystic nodules is supported by its high effectiveness and good safety profile compared to other currently available non-surgical options.

Citations

Citations to this article as recorded by

Ultrasound-guided ethanol ablation versus the Sistrunk operation as a primary treatment for thyroglossal duct cysts
Dongbin Ahn, Ji Hye Kwak, Gil Joon Lee, Jin Ho Sohn
Ultrasonography.2024; 43(1): 25. CrossRef
The Comparison of Efficacy and Safety between Radiofrequency Ablation Alone and Ethanol Ablation Followed by Radiofrequency Ablation in the Treatment of Mixed Cystic and Solid Thyroid Nodule
Min Gang Jo, Min Kyoung Lee, Jae Ho Shin, Min Guk Seo, So Lyung Jung
Journal of the Korean Society of Radiology.2024; 85(3): 618. CrossRef
Prevalence and Management of Complications of Percutaneous Ethanol Injection for Cystic Thyroid Nodules: A Systematic Review of Literature and Meta-analysis
Lorenzo Scappaticcio, Pamela Ferrazzano, Nicole Di Martino, Roberto Negro, Maurilio Deandrea, Maria Ida Maiorino, Paola Caruso, Michela Di Nuzzo, Miriam Longo, Giovanni Docimo, Giampaolo Papi, Pierpaolo Trimboli, Katherine Esposito, Giuseppe Bellastella
Thyroid®.2024; 34(9): 1068. CrossRef
Current role of interventional radiology in thyroid nodules
Onur Taydas, Erbil Arik, Omer Faruk Sevinc, Ahmet Burak Kara, Mustafa Ozdemir, Hasret Cengiz, Zulfu Bayhan, Mehmet Halil Ozturk
Frontiers in Endocrinology.2024;[Epub] CrossRef
Ethanol Ablation Is a Safe Treatment Option for Cystic and Predominantly Cystic Thyroid Nodules
Iram Hussain
Clinical Thyroidology®.2024; 36(11): 412. CrossRef
Percutaneous Ethanol Sclerotherapy for Head-and-Neck Lymphatic Malformation: A Systematic Review and Case Report
Xin Ler Pang, Stephanie He Shengjie, Man Hon Tang, Joel Lau Wen Liang, Wei Keat Cheah, Yi-Xiu Chua, Hui Seong Teh, Si Zhao Tang
Journal of Endocrine Surgery.2024; 24(4): 119. CrossRef
Ultrasound-Guided Ethanol Ablation for Thyroglossal Duct Cyst: A Review of Technical Issues and Potential as a New Standard Treatment
Dongbin Ahn
Journal of Clinical Medicine.2023; 12(17): 5445. CrossRef
Ultrasound‐Guided Ethanol Ablation as a Primary Treatment for Thyroglossal Duct Cyst: Feasibility, Characteristics, and Outcomes
Dongbin Ahn, Ji Hye Kwak, Gil Joon Lee, Jin Ho Sohn
Otolaryngology–Head and Neck Surgery.2023; 168(6): 1381. CrossRef
Ultraschallgeführte lokalablative Verfahren zur Behandlung von Schilddrüsenläsionen
Johannes-Paul Richter, Carl-Philip Richter, Daniel Gröner
Angewandte Nuklearmedizin.2023; 46(02): 169. CrossRef
A Case of Thyroid Abscess Following Ethanol Ablation for Benign Thyroid Nodule
Heungrae Cho, Dongbin Ahn, Ji Hye Kwak, Gil Joon Lee
Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2023; 66(9): 624. CrossRef
Sclerotherapy with a Viscum Album Extract for the Two Patients with Cystic Thyroid Nodule
Jae Ha Lee, Seung Won Lee, Ki Nam Park
International Journal of Thyroidology.2023; 16(1): 139. CrossRef
Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies: A systematic review, meta-analysis and economic evaluation
Beatriz León-Salas, Aránzazu Hernández-Yumar, Diego Infante-Ventura, Aythami de Armas Castellano, Yadira González Hernández, Renata Linertová, Teresa Téllez Santana, Pedro de Pablos-Velasco, María M. Trujillo-Martín
Endocrinología, Diabetes y Nutrición.2023; 70(9): 572. CrossRef
Ultraschallgeführte lokalablative Verfahren zur Behandlung von Schilddrüsenläsionen
Johannes-Paul Richter, Carl-Philip Richter, Daniel Gröner
Laryngo-Rhino-Otologie.2023; 102(12): 916. CrossRef
Percutaneous ethanol injection in thyroid nodular pathology and metastatic cervical adenopathies: A systematic review, meta-analysis and economic evaluation
Beatriz León-Salas, Aránzazu Hernández-Yumar, Diego Infante-Ventura, Aythami de Armas Castellano, Yadira González Hernández, Renata Linertová, Teresa Téllez Santana, Pedro de Pablos-Velasco, María M. Trujillo-Martín
Endocrinología, Diabetes y Nutrición (English ed.).2023; 70(9): 572. CrossRef
Safety and Efficacy of Ultrasound-Guided Radiofrequency Ablation for Benign Nonfunctional Thyroid Nodules in Children: A Retrospective Study of 62 Patients with Over Four Years of Follow-Up
Liwen Li, Xinguang Qiu
Thyroid.2022; 32(5): 525. CrossRef
Ethanol ablation for the treatment of benign thyroid nodules
Gabrielle K. Steinl, Latoya A. Stewart, Catherine McManus, James A. Lee, Jennifer H. Kuo
The American Journal of Surgery.2022; 224(1): 408. CrossRef
Minimally-invasive treatments for benign thyroid nodules: recommendations for information to patients and referring physicians by the Italian Minimally-Invasive Treatments of the Thyroid group
Giovanni Mauri, Stella Bernardi, Andrea Palermo, Roberto Cesareo, Enrico Papini, Luigi Solbiati, Daniele Barbaro, Salvatore Monti, Maurilio Deandrea, Laura Fugazzola, Giovanni Gambelunghe, Roberto Negro, Stefano Spiezia, Fulvio Stacul, Luca Maria Sconfien
Endocrine.2022; 76(1): 1. CrossRef
Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors
Arian Mansur, Tushar Garg, Apurva Shrigiriwar, Vahid Etezadi, Christos Georgiades, Peiman Habibollahi, Timothy C. Huber, Juan C. Camacho, Sherif G. Nour, Alan Alper Sag, John David Prologo, Nariman Nezami
Diagnostics.2022; 12(6): 1300. CrossRef
Approach to FNA of Thyroid Gland Cysts
Esther Diana Rossi, Pietro Tralongo, Vincenzo Fiorentino, Mariangela Curatolo, Carmine Bruno, Carmen De Crea, Marco Raffaelli, Alfredo Pontecorvi, Luigi Maria Larocca
Advances in Anatomic Pathology.2022; 29(6): 358. CrossRef

Clinical Study
The Association of Overt and Subclinical Hyperthyroidism with the Risk of Cardiovascular Events and Cardiovascular Mortality: Meta-Analysis and Systematic Review of Cohort Studies: Seo Young Sohn, Eunyoung Lee, Min Kyung Lee, Jae Hyuk Lee; Endocrinol Metab. 2020;35(4):786-800. Published online November 25, 2020; DOI: https://doi.org/10.3803/EnM.2020.728

8,476 View
332 Download
32 Web of Science
34 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Whether hyperthyroidism is an independent risk factor for cardiovascular events remains controversial. We aimed to evaluate the association of overt and subclinical hyperthyroidism with the risk of ischemic heart disease (IHD), stroke, heart failure, and cardiovascular mortality.
Methods
Studies regarding the association between hyperthyroidism and cardiovascular events were searched on PubMed and Embase databases. The cardiovascular disease (CVD) risk was classified as high and low, based on pre-existing diseases, including history of coronary, cerebral, or peripheral artery disease; heart failure; atrial fibrillation; diabetes mellitus; or chronic kidney disease.
Results
Thirty-seven cohort studies were included in this meta-analysis. The pooled hazard ratio for subjects with overt hyperthyroidism compared with the control group was 1.11 (95% confidence interval [CI], 1.03 to 1.19) for IHD, 1.35 (95% CI, 1.03 to 1.75) for stroke, and 1.20 (95% CI, 1.00 to 1.46) for cardiovascular mortality. For subjects with subclinical hyperthyroidism, the pooled hazard ratio was 1.24 (95% CI, 1.07 to 1.45) for IHD, when compared with the control group. Subgroup analysis by CVD risk showed that the risk of stroke in overt hyperthyroidism was increased in the low CVD risk group; however, these association was not observed in the high CVD risk group. Similarly, the risk of IHD in subjects with subclinical hyperthyroidism was significantly increased in the low CVD risk group.
Conclusion
Overt hyperthyroidism is associated with increased risk of IHD, stroke, and cardiovascular mortality, and subclinical hyperthyroidism is associated with increased risk of IHD. These associations were particularly observed in the low risk CVD group without underlying CVD.

Citations

Citations to this article as recorded by

Establishing the TSH reference intervals for healthy adults aged over 70 years: the Australian ASPREE cohort study
Cammie Tran, Duncan J. Topliss, Hans G. Schneider, Ego Seeman, Daniel Clayton-Chubb, Johannes T. Neumann, Nadira Kakoly, Zhen Zhou, Sultana Monira Hussain, Amanda J. Rickard, David P.Q. Clark, Raj C. Shah, Robyn L. Woods, John J. McNeil
Clinical Chemistry and Laboratory Medicine (CCLM).2025; 63(3): 611. CrossRef
Trends in Prevalence of Thyroid Dysfunction and its Associations With Mortality Among US Participants, 1988-2012
Xiaowen Zhang, Yong Wang, Hongwei Wang, Xinlin Zhang
The Journal of Clinical Endocrinology & Metabolism.2024; 109(2): e657. CrossRef
Adequacy of thyroid hormone replacement for people with hypothyroidism in real‐world settings: A systematic review and meta‐analysis of observational studies
Agathoklis Efthymiadis, Matthew Henry, Dimitrios Spinos, Marianthi Bourlaki, Alexandros Tsikopoulos, Angeliki Bourazana, Anastasios Bastounis, Konstantinos Tsikopoulos
Clinical Endocrinology.2024; 100(5): 488. CrossRef
Thyroid Disorders and Peripheral Arterial Disease
Katica Bajuk Studen, Simona Gaberscek, Katja Zaletel, Ales Blinc, Miso Sabovic, Gerit-Holger Schernthaner, Panagiotis Anagnostis, Pier Luigi Antignani, Mojca Jensterle, Dimitri P Mikhailidis, Pavel Poredos
Current Vascular Pharmacology.2024; 22(1): 36. CrossRef
Hormonal influences on cerebral aneurysms: unraveling the complex connections
Zahra Hasanpour Segherlou, Mahdieh Shakeri-Darzekonani, Armin Khavandegar, Sara Stephenson, Kimberly Ciccone, Forough Masheghati, Mohammad Reza Hosseini Siyanaki, Mac Lyerly, Brandon Lucke-Wold
Expert Review of Endocrinology & Metabolism.2024; 19(3): 207. CrossRef
Pulmonary Embolism in Patients Admitted With Takotsubo Cardiomyopathy: Prevalence and Associated In-Hospital Adverse Events
Omar Elkattawy, Antonia Sames, Sruthi Kunamneni , Riya Sutariya , Mohamed Ismail, Omar Mohamed , Thomas J Lee, Jahanzeb Javed, Sherif Elkattawy, Afif Hossain, Fayez Shamoon
Cureus.2024;[Epub] CrossRef
Thyroid Disorders
Gauri Dhir, Vasudha Jain, Andrew Merritt
Primary Care: Clinics in Office Practice.2024; 51(3): 405. CrossRef
The effect of hypothyroidism on cardiovascular events and type 2 diabetes mellitus developing in rheumatoid arthritis
Liubov V. Kondratyeva, Tatiana V. Popkova, Evgeny L. Nasonov
Terapevticheskii arkhiv.2024; 96(5): 459. CrossRef
2024 ESC Guidelines for the management of chronic coronary syndromes
Christiaan Vrints, Felicita Andreotti, Konstantinos C Koskinas, Xavier Rossello, Marianna Adamo, James Ainslie, Adrian Paul Banning, Andrzej Budaj, Ronny R Buechel, Giovanni Alfonso Chiariello, Alaide Chieffo, Ruxandra Maria Christodorescu, Christi Deaton
European Heart Journal.2024; 45(36): 3415. CrossRef
Zinc and Ferritin Levels and Their Associations with Functional Disorders and/or Thyroid Autoimmunity: A Population-Based Case–Control Study
Hernando Vargas-Uricoechea, Karen Urrego-Noguera, Hernando Vargas-Sierra, María Pinzón-Fernández
International Journal of Molecular Sciences.2024; 25(18): 10217. CrossRef
Magnitude of cardiac abnormality and its associated factors among hyperthyroidism patients on follow-up at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia
Bayu Hailemariam Mersha, Senbeta Guteta Abdissa, Theodros Aberra Alemneh, Natnael Kebede, Yawkal Tsega, Shambel Nigussie, Fekade Demeke Bayou
BMC Cardiovascular Disorders.2024;[Epub] CrossRef
The impact of thyroid disorder on cardiovascular disease: Unraveling the connection and implications for patient care
Nanny Natalia Mulyani Soetedjo, Dessy Agustini, Hikmat Permana
IJC Heart & Vasculature.2024; 55: 101536. CrossRef
Modern concepts of managing patients with thyrotoxic heart
M.N. Mamedov, N.M. Akhmedzhanov, Kh.R. Akhundova
Russian Journal of Preventive Medicine.2024; 27(10): 125. CrossRef
Impact of sleep restriction on biomarkers of thyroid function: Two pooled randomized trials
Megan E. Petrov, Faris M. Zuraikat, Bin Cheng, Brooke Aggarwal, Sanja Jelic, Blandine Laferrère, Marie-Pierre St-Onge
Sleep Medicine.2024; 124: 606. CrossRef
Association between atherosclerosis and the development of multi-organ pathologies
Siarhei A Dabravolski, Alexey V Churov, Natalia V Elizova, Alessio L Ravani, Amina E Karimova, Vasily N Sukhorukov, Alexander N Orekhov
SAGE Open Medicine.2024;[Epub] CrossRef
Higher Risk of Incident Hyperthyroidism in Patients With Atrial Fibrillation
Pang-Shuo Huang, Jen-Fang Cheng, Jien-Jiun Chen, Yi-Chih Wang, Juey-Jen Hwang, Cho-Kai Wu, Chia-Ti Tsai
The Journal of Clinical Endocrinology & Metabolism.2023; 109(1): 92. CrossRef
Eurasian clinical guidelines for the diagnosis and treatment of secondary (symptomatic) forms of arterial hypertension (2022)
I. E. Chazova, N. M. Chikhladze, N. V. Blinova, Zh. E. Belaya, N. M. Danilov, E. M. Elfimova, A. Yu. Litvin, L. Ya. Rozhinskaya, N. Yu. Sviridenko, M. Yu. Shvetsov, V. A. Azizov, E. A. Grigorenko, N. P. Mit’kovskaja, I. I. Mustafaev, A. G. Polupanov, A. S
Eurasian heart journal.2023; (1): 6. CrossRef
Sympathetic Activation Promotes Cardiomyocyte Apoptosis in a Rabbit Susceptibility Model of Hyperthyroidism-Induced Atrial Fibrillation via the p38 MAPK Signaling Pathway
Jialin Zheng, Shijian Zhao, Qishi Yang, Yantao Wei, Jianmei Li, Tao Guo
Critical Reviews in Eukaryotic Gene Expression.2023; 33(5): 17. CrossRef
Cardiovascular outcomes in subclinical thyroid disease: an update
Matthew D. Ettleson
Current Opinion in Endocrinology, Diabetes & Obesity.2023;[Epub] CrossRef
Lower free triiodothyronine levels are associated with higher all-cause and cardiovascular mortality in people with diabetes-NHANES 2007–2012
Chang Liu, Zhong Xin, Lin Hua
Diabetes Research and Clinical Practice.2023; 202: 110811. CrossRef
Hyperthyroidism
Sun Y. Lee, Elizabeth N. Pearce
JAMA.2023; 330(15): 1472. CrossRef
Is Thyroid Dysfunction Associated with Unruptured Intracranial Aneurysms? A Population-Based, Nested Case–Control Study from Korea
Hyeree Park, Sun Wook Cho, Sung Ho Lee, Kangmin Kim, Hyun-Seung Kang, Jeong Eun Kim, Aesun Shin, Won-Sang Cho
Thyroid®.2023; 33(12): 1483. CrossRef
Risks of suboptimal and excessive thyroid hormone replacement across ages
U. Feldt-Rasmussen, G. Effraimidis, S. Bliddal, M. Klose
Journal of Endocrinological Investigation.2023; 47(5): 1083. CrossRef
Association of Mild Thyroid Dysfunction and Adverse Prognosis Among Chinese Patients With Acute ST Segment Elevation Myocardial Infarction
Mei-Fang Li, Ze-Tao Wei, Shuai Li, Qi-Ming Feng, Jing-Bo Li
Frontiers in Endocrinology.2022;[Epub] CrossRef
The Cardiovascular Effects of Subclinical Hyperthyroidism following Percutaneous Coronary Intervention
Ricardo Correa, Ricardo Villela
Clinical Thyroidology.2022; 34(6): 240. CrossRef
Weight Gain and Body Composition Changes during the Transition of Thyroid Function in Patients with Graves’ Disease Undergoing Radioiodine Treatment
Zhenqin Cai, Qiyu Chen, Yan Ling, Henrik Falhammar
International Journal of Endocrinology.2022; 2022: 1. CrossRef
Minor perturbations of thyroid homeostasis and major cardiovascular endpoints—Physiological mechanisms and clinical evidence
Patrick Müller, Melvin Khee-Shing Leow, Johannes W. Dietrich
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Role of thyroid hormones-induced oxidative stress on cardiovascular physiology
María Laura Barreiro Arcos
Biochimica et Biophysica Acta (BBA) - General Subjects.2022; 1866(12): 130239. CrossRef
Yearly Incidence of Stroke and Bleeding in Atrial Fibrillation with Concomitant Hyperthyroidism: A National Discharge Database Study
Juqian Zhang, Arnaud Bisson, Grégoire Fauchier, Alexandre Bodin, Julien Herbert, Pierre Henri Ducluzeau, Gregory Y. H. Lip, Laurent Fauchier
Journal of Clinical Medicine.2022; 11(5): 1342. CrossRef
Platelet abnormalities in autoimmune thyroid diseases: A systematic review and meta-analysis
Yu-tian Cao, Kai-yu Zhang, Jing Sun, Yan Lou, Tian-su Lv, Xinyi Yang, Wen-hui Zhang, Jiang-yi Yu, Qi-biao Wu, Xi-qiao Zhou
Frontiers in Immunology.2022;[Epub] CrossRef
Subclinical Hyperthyroidism: A Review of the Clinical Literature
Karen Tsai, Angela M. Leung
Endocrine Practice.2021; 27(3): 254. CrossRef
Thyroid and heart, a clinically relevant relationship
G. Corona, L. Croce, C. Sparano, L. Petrone, A. Sforza, M. Maggi, L. Chiovato, M. Rotondi
Journal of Endocrinological Investigation.2021; 44(12): 2535. CrossRef
Antithyroid Drug Treatment in Graves’ Disease
Jae Hoon Chung
Endocrinology and Metabolism.2021; 36(3): 491. CrossRef
Cardiovascular Outcomes in Thyroid Cancer Patients Treated With Thyroidectomy: A Meta-Analysis
Eun Kyung Lee, Hwa Young Ahn, Eu Jeong Ku, Won Sang Yoo, Young Ki Lee, Kee-Hyun Nam, Young Jun Chai, Shinje Moon, Yuh-Seog Jung
The Journal of Clinical Endocrinology & Metabolism.2021;[Epub] CrossRef

Clinical Study
Long-Term Results of Thermal Ablation of Benign Thyroid Nodules: A Systematic Review and Meta-Analysis: Se Jin Cho, Jung Hwan Baek, Sae Rom Chung, Young Jun Choi, Jeong Hyun Lee; Endocrinol Metab. 2020;35(2):339-350. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.339

13,158 View
344 Download
51 Web of Science
57 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Ultrasound-guided thermal ablations have become one of the main options for treating benign thyroid nodules. To determine efficacy of thermal ablation of benign thyroid nodules, we performed a meta-analysis of studies with long-term follow-up of more than 3 years.
Methods
Databases were searched for studies published up to August 25, 2019, reporting patients with benign thyroid nodules treated with thermal ablation and with follow-up data of more than 3 years. Data extraction and quality assessment were performed according to PRISMA guidelines. The analysis yielded serial volume reduction rates (VRRs) of ablated nodules for up to 3 years or more, and adverse effect of ablation during follow-up. Radiofrequency ablation (RFA) and laser ablation (LA) were compared in a subgroup analysis.
Results
The pooled VRRs for ablated nodules showed rapid volume reduction before 12 months, a plateau from 12 to 36 months, and more volume reduction appearing after 36 months, demonstrating long-term maintenance of treatment efficacy. Thermal ablation had an acceptable complication rate of 3.8%. Moreover, patients undergoing nodule ablation showed no unexpected delayed complications during the follow-up period. In the subgroup analysis, RFA was shown to be superior to LA in terms of the pooled VRR and the number of patients who underwent delayed surgery.
Conclusion
Thermal ablations are safe and effective methods for treating benign thyroid nodules, as shown by a long follow-up analysis of more than 3 years. In addition, RFA showed superior VRRs compared with LA for the treatment of benign thyroid nodules, with less regrowth and less delayed surgery.

Citations

Citations to this article as recorded by

Radiofrequency Ablation of Benign Thyroid Nodules: 10-Year Follow-Up Results From a Single Center
Jae Ho Shin, Minkook Seo, Min Kyoung Lee, So Lyung Jung
Korean Journal of Radiology.2025; 26(2): 193. CrossRef
Five-year follow-up results of thermal ablation for benign thyroid nodules: Systematic review and meta-analysis
Xidong Xu, Ying Peng, Guoxin Han
American Journal of Otolaryngology.2024; 45(1): 104025. CrossRef
Radiofrequency Ablation for Benign Nodules and for Cancer, Too?
Jonathon O. Russell, Kaitlyn M. Frazier
Otolaryngologic Clinics of North America.2024; 57(1): 83. CrossRef
An anthropomorphic thyroid phantom for ultrasound‐guided radiofrequency ablation of nodules
Tim Boers, Wyger Brink, Leonardo Bianchi, Paola Saccomandi, Johan van Hespen, Germen Wennemars, Sicco Braak, Michel Versluis, Srirang Manohar
Medical Physics.2024; 51(2): 826. CrossRef
The safety and efficacy of radiofrequency ablation in benign pediatric thyroid disease in the US: An initial case series
Grace S. Kim, Hilary Seeley, Julia Noel, Iram Ahmad, Kara Meister
Laryngoscope Investigative Otolaryngology.2024;[Epub] CrossRef
Radioiodine versus radiofrequency ablation to treat autonomously functioning thyroid nodules: a systematic review and comparative meta-analysis
Luca Giovanella, Maria Luisa Garo, Alfredo Campenní, Petra Petranović Ovčariček
European Journal of Nuclear Medicine and Molecular Imaging.2024; 51(7): 2050. CrossRef
Novel and Advanced Ultrasound Techniques for Thyroid Thermal Ablation
Wai-Kin Chan, Jui-Hung Sun, Miaw-Jene Liou, Chia-Jung Hsu, Yu-Ling Lu, Wei-Yu Chou, Yan-Rong Li, Feng-Hsuan Liu
Endocrinology and Metabolism.2024; 39(1): 40. CrossRef
Sublethal thermal stress promotes migration and invasion of thyroid cancer cells
Chi-Yu Kuo, Chung-Hsin Tsai, Jun Kui Wu, Shih-Ping Cheng, Yi-Hsien Hsieh
PLOS ONE.2024; 19(2): e0298903. CrossRef
The Role of Radiofrequency Ablation in Benign and Malignant Thyroid Nodules
Meghal Shah, Catherine McManus
Surgical Clinics of North America.2024; 104(4): 779. CrossRef
Comparison of ultrasound-guided microwave ablation, laser ablation, and radiofrequency ablation for the treatment of elderly patients with benign thyroid nodules: A meta-analysis
Ying Qian, Zheng Li, Chunyun Fan, Yong Huang
Experimental Gerontology.2024; 191: 112425. CrossRef
Assessing the relative effectiveness of various ultrasound-guided ablation techniques for treating benign thyroid nodules: A systematic review and network meta-analysis
Xiangmei Sun, Jiaojiao Chen, Yan Zou, Jiahao Lei, Weizong Liu
Medicine.2024; 103(18): e38014. CrossRef
Benign Thyroid Nodules Respond Better to Thermal Ablation Retreatment If They Are Smaller
Iram Hussain
Clinical Thyroidology®.2024; 36(5): 199. CrossRef
Adjustable-tip needles versus fixed-tip needles in radiofrequency ablation of symptomatic benign thyroid nodules: a single-center Italian experience
Mattia Rossi, Letizia Meomartino, Loredana Pagano, Giulia Follini, Sara Garberoglio, Mauro Maccario, Ruth Rossetto Giaccherino, Roberto Garberoglio
Journal of Ultrasound.2024; 27(3): 699. CrossRef
Brazilian Consensus on the Application of Thermal Ablation for Treatment of Thyroid Nodules: A Task Force Statement by the Brazilian Society of Interventional Radiology and Endovascular Surgery (SOBRICE), Brazilian Society of Head and Neck Surgery (SBCCP)
Gustavo Philippi de los Santos, Marco Aurélio Vamondes Kulcsar, Fabio de Aquino Capelli, Jose Higino Steck, Klecius Leite Fernandes, Cleo Otaviano Mesa, Joaquim Mauricio da Motta-Leal-Filho, Rafael Selbach Scheffel, Fernanda Vaisman, Guilherme Lopes Pinhe
Archives of Endocrinology and Metabolism.2024;[Epub] CrossRef
A 6-year single-center prospective follow-up study of the efficacy of radiofrequency ablation for thyroid nodules
Shi Chuanke, Luo Ming, Yan Zhideng, Liu Huan
Frontiers in Endocrinology.2024;[Epub] CrossRef
Comparative efficacy and safety of radiofrequency ablation and microwave ablation in benign thyroid nodule treatment: a systematic review and meta-analysis
Hunjong Lim, Se Jin Cho, Jung Hwan Baek
European Radiology.2024; 35(2): 612. CrossRef
Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules: 10-Year Experience
Sang Ik Park, Jung Hwan Baek, Da Hyun Lee, Sae Rom Chung, Dong Eun Song, Won Gu Kim, Tae Yong Kim, Tae-Yon Sung, Ki-Wook Chung, Jeong Hyun Lee
Thyroid®.2024; 34(8): 990. CrossRef
Current role of interventional radiology in thyroid nodules
Onur Taydas, Erbil Arik, Omer Faruk Sevinc, Ahmet Burak Kara, Mustafa Ozdemir, Hasret Cengiz, Zulfu Bayhan, Mehmet Halil Ozturk
Frontiers in Endocrinology.2024;[Epub] CrossRef
The first experience of applying microwave ablation in primary hyperparathyroidism
M. B. Saliba, S. P. Vetshev, A. A. Maksimova, G. A. Zhemerikin, F. P. Vetshev, V. A. Zhivova, K. K. Popov, E. А. Pavlova
Grekov's Bulletin of Surgery.2024; 183(3): 62. CrossRef
Long-term clinical outcomes of thermal ablation for benign thyroid nodules and unresolved issues: a comprehensive systematic review
So Yeong Jeong, Jung Hwan Baek
La radiologia medica.2024;[Epub] CrossRef
Ultrasound‐Guided Thermal Ablation Versus Thyroidectomy in the Treatment of Benign Thyroid Nodules
Ruaa Mustafa Qafesha, Muataz Kashbour, Sarah Amro, Mahmoud Diaa Hindawi, Menna Elbadry, Asem Ahmed Ghalwash, Zeinab Alnatsheh, Mahmoud A.Y Abdelaziz, Hatem Eldeeb, Ahmad Ramzi Shiha
Journal of Ultrasound in Medicine.2024;[Epub] CrossRef
Ultrasound imaging in thyroid nodule diagnosis, therapy, and follow‐up: Current status and future trends
Tim Boers, Sicco J. Braak, Nicole E. T. Rikken, Michel Versluis, Srirang Manohar
Journal of Clinical Ultrasound.2023; 51(6): 1087. CrossRef
Ultrasound (US)-Guided Ablation of Thyroid Nodules
Byung Seup Kim
Journal of Surgical Ultrasound.2023; 10(1): 14. CrossRef
Ultrasound-Guided Radiofrequency Ablation versus Thyroidectomy for the Treatment of Benign Thyroid Nodules in Elderly Patients: A Propensity-Matched Cohort Study
L. Yan, X.Y. Li, Y. Li, Y. Luo
American Journal of Neuroradiology.2023; 44(6): 693. CrossRef
Minimally Invasive Ablative Treatments for Benign Thyroid Nodules: Current Evidence and Future Directions
Enrico Papini, Laszlo Hegedüs
Thyroid®.2023; 33(8): 890. CrossRef
Influence factors and nomogram for volume reduction rate in benign thyroid nodule after thermal ablation
Shiliang Cao, Lijia Wang, Ying Wei, Zhenlong Zhao, Jie Wu, Mingan Yu
International Journal of Hyperthermia.2023;[Epub] CrossRef
Choice in Ablative Therapies for Thyroid Nodules
Q Lina Hu, Jennifer H Kuo
Journal of the Endocrine Society.2023;[Epub] CrossRef
2022 Taiwan clinical multicenter expert consensus and recommendations for thyroid radiofrequency ablation
Wei-Che Lin, Wen-Chieh Chen, Pei-Wen Wang, Yi-Chia Chan, Yen-Hsiang Chang, Harn-Shen Chen, Szu-Tah Chen, Wei-Chih Chen, Kai-Lun Cheng, Shun-Yu Chi, Pi-Ling Chiang, Chen-Kai Chou, Feng-Fu Chou, Shun-Chen Huang, Feng-Hsuan Liu, Sheng-Dean Luo, Fen-Yu Tseng,
Ultrasonography.2023; 42(3): 357. CrossRef
Comparison of the Efficiency of Radiofrequency and Microwave Ablation Methods in the Treatment of Benign Thyroid Nodules
Mahi N. Cerit, Cem Yücel, Ethem T. Cerit, Mehmet M. Yalçın, Halit N. Şendur, Suna Ö. Oktar
Academic Radiology.2023; 30(10): 2172. CrossRef
Radiofrequency ablation for autonomously functioning nodules as treatment for hyperthyroidism: subgroup analysis of toxic adenoma and multinodular goitre and predictors for treatment success
M. M. D. van der Meeren, F. B. M. Joosten, S. H. P. P. Roerink, L. N. Deden, W. J. G. Oyen
European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(12): 3675. CrossRef
Massive Hemorrhage and Mortality Following Thyroid Radiofrequency Ablation
Seulki Song, Jin Pyeong Kim
Ear, Nose & Throat Journal.2023;[Epub] CrossRef
Clinical Approach for Thyroid Radiofrequency Ablation
Jung Suk Sim
Journal of the Korean Society of Radiology.2023; 84(5): 1017. CrossRef
General Principles for the Safe Performance, Training, and Adoption of Ablation Techniques for Benign Thyroid Nodules: An American Thyroid Association Statement
Catherine F. Sinclair, Jung Hwan Baek, Kathleen E. Hands, Steven P. Hodak, Timothy C. Huber, Iram Hussain, Brian Hung-Hin Lang, Julia E. Noel, Maria Papaleontiou, Kepal N. Patel, Gilles Russ, Jonathon Russell, Stefano Spiezia, Jennifer H. Kuo
Thyroid®.2023; 33(10): 1150. CrossRef
A comprehensive review of interventional ablation techniques for the management of thyroid nodules and metastatic lymph nodes
Jennifer H. Kuo, Catherine F. Sinclair, Brian Lang, Stefano Spiezia, Mingan Yu, Eun Ju Ha, Dong Gyu Na, Chiara Offi, Kepal N. Patel, Jung Hwan Baek
Surgery.2022; 171(4): 920. CrossRef
Radiofrequency ablation and related ultrasound‐guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with
Lisa A. Orloff, Julia E. Noel, Brendan C. Stack, Marika D. Russell, Peter Angelos, Jung Hwan Baek, Kevin T. Brumund, Feng‐Yu Chiang, Mary Beth Cunnane, Louise Davies, Andrea Frasoldati, Anne Y. Feng, Laszlo Hegedüs, Ayaka J. Iwata, Emad Kandil, Jennifer K
Head & Neck.2022; 44(3): 633. CrossRef
Assessment of thyroid-specific quality of life in patients with benign symptomatic thyroid nodules treated with radiofrequency or ethanol ablation: a prospective multicenter study
So Yeong Jeong, Eun Ju Ha, Jung Hwan Baek, Tae Yong Kim, Yu-Mi Lee, Jeong Hyun Lee, Jeonghun Lee
Ultrasonography.2022; 41(1): 204. CrossRef
Thyroid Nodule Radiofrequency Ablation: Complications and Clinical Follow Up
James Y. Lim, Jennifer H. Kuo
Techniques in Vascular and Interventional Radiology.2022; 25(2): 100824. CrossRef
Radiofrequency Ablation of Solid, Non-Functional Thyroid Nodules
Michael Douek
Techniques in Vascular and Interventional Radiology.2022; 25(2): 100821. CrossRef
Efficacy and Safety of Thermal Ablation for Treating Lymph Node Metastasis From Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis
Zheng Ding, Juan Chen, Zhiguang Chen, Xiaoke Zeng, Pengchao Zheng, Xuemei Wang, Xinwu Cui, Liang Sang
Frontiers in Oncology.2022;[Epub] CrossRef
Intraoperative Neuromonitoring: Evaluating the Role of Continuous IONM and IONM Techniques for Emerging Surgical and Percutaneous Procedures
Catherine McManus, Jennifer Hong Kuo
Frontiers in Endocrinology.2022;[Epub] CrossRef
Thermal Ablation for the Management of Papillary Thyroid Microcarcinoma in the Era of Active Surveillance and Hemithyroidectomy
Sae Rom Chung, Jung Hwan Baek, Young Jun Choi, Jeong Hyun Lee
Current Oncology Reports.2022; 24(8): 1045. CrossRef
enhanced anarchic society optimization technique for the classification of ultrasound thyroid images using ILBP
D. Anitha, S. Sathya Priya
International journal of health sciences.2022; : 4713. CrossRef
Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors
Arian Mansur, Tushar Garg, Apurva Shrigiriwar, Vahid Etezadi, Christos Georgiades, Peiman Habibollahi, Timothy C. Huber, Juan C. Camacho, Sherif G. Nour, Alan Alper Sag, John David Prologo, Nariman Nezami
Diagnostics.2022; 12(6): 1300. CrossRef
Efficacy and safety of ultrasound-guided microwave ablation versus surgical resection for Bethesda category IV thyroid nodules: A retrospective comparative study
Jingjing Yang, Ya Zhang, Xingjia Li, Yueting Zhao, Xue Han, Guofang Chen, Xiaoqiu Chu, Ruiping Li, Jianhua Wang, Fei Huang, Chao Liu, Shuhang Xu
Frontiers in Endocrinology.2022;[Epub] CrossRef
Long-term follow-up of the radiofrequency ablation of benign thyroid nodules: the value of additional treatment
Hyun Jin Kim, Jung Hwan Baek, Woojin Cho, Jung Suk Sim
Ultrasonography.2022; 41(4): 661. CrossRef
Das „heiße“ Schilddrüsenkarzinom mit einem kritischen Blick auf die Thermoablation
Joachim Jähne, Andreas Niesen, Joachim Bernhardts, Marija Hillemans
Der Chirurg.2021; 92(1): 34. CrossRef
Current Practice of Percutaneous Ablation Technologies for Thyroid Nodules 2020
Haris Muhammad, Jonathon O. Russell, Prasanna Santhanam, Aniqa Tehreem, Ralph P. Tufano
Current Otorhinolaryngology Reports.2021; 9(1): 52. CrossRef
RFA and benign thyroid nodules: Review of the current literature
Haris Muhammad, Prasanna Santhanam, Jonathon O. Russell, Jennifer H. Kuo
Laryngoscope Investigative Otolaryngology.2021; 6(1): 155. CrossRef
Thermal Treatment Options for Benign Thyroid Nodules—The Role of Radio-Frequency Ablation and Laser Therapy
Erivelto Volpi
Clinical Thyroidology.2021; 33(1): 17. CrossRef
Comparative efficacy of different ultrasound-guided ablation for the treatment of benign thyroid nodules: Systematic review and network meta-analysis of randomized controlled trials
Linye He, Wanjun Zhao, Zijing Xia, Anping Su, Zhihui Li, Jingqiang Zhu, Ivan D. Florez
PLOS ONE.2021; 16(1): e0243864. CrossRef
Unresolved Clinical Issues in Thermal Ablation of Benign Thyroid Nodules: Regrowth at Long-Term Follow-Up
Jung Suk Sim, Jung Hwan Baek
Korean Journal of Radiology.2021; 22(8): 1436. CrossRef
Current Status and Challenges of US-Guided Radiofrequency Ablation of Thyroid Nodules in the Long Term: A Systematic Review
Stella Bernardi, Andrea Palermo, Rosario Francesco Grasso, Bruno Fabris, Fulvio Stacul, Roberto Cesareo
Cancers.2021; 13(11): 2746. CrossRef
Update of Radiofrequency Ablation for Treating Benign and Malignant Thyroid Nodules. The Future Is Now
Ralph P. Tufano, Pia Pace-Asciak, Jonathon O. Russell, Carlos Suárez, Gregory W. Randolph, Fernando López, Ashok R. Shaha, Antti Mäkitie, Juan P. Rodrigo, Luiz Paulo Kowalski, Mark Zafereo, Peter Angelos, Alfio Ferlito
Frontiers in Endocrinology.2021;[Epub] CrossRef
Factors Associated with the Efficacy of Radiofrequency Ablation in the Treatment of Benign Thyroid Nodules
Huynh Q Khanh, Nguyen L Vuong, Tran Q Tien
World Journal of Endocrine Surgery.2021; 12(3): 117. CrossRef
Long-Term Outcomes of Thermal Ablation for Benign Thyroid Nodules: The Issue of Regrowth
Jung Suk Sim, Jung Hwan Baek, Rosaria Meccariello
International Journal of Endocrinology.2021; 2021: 1. CrossRef
Matrix 3D ultrasound-assisted thyroid nodule volume estimation and radiofrequency ablation: a phantom study
T. Boers, S. J. Braak, M. Versluis, S. Manohar
European Radiology Experimental.2021;[Epub] CrossRef
Learning curve analysis of radiofrequency ablation for benign thyroid nodules
Chi-Yu Kuo, Chien-Liang Liu, Chung-Hsin Tsai, Shih-Ping Cheng
International Journal of Hyperthermia.2021; 38(1): 1536. CrossRef

Clinical Study
Association between Circulating Irisin and C-Reactive Protein Levels: A Systematic Review and Meta-Analysis: Elham Eslampour, Farzad Ebrahimzadeh, Amir Abbasnezhad, Mohammad Zeinali Khosroshahi, Razieh Choghakhori, Omid Asbaghi; Endocrinol Metab. 2019;34(2):140-149. Published online June 24, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.2.140

5,668 View
65 Download
13 Web of Science
14 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Although previous studies have demonstrated that irisin plays an anti-inflammatory role in the body, conflicting results have been reported regarding the correlation between serum levels of irisin and C-reactive protein (CRP). The present meta-analysis was conducted to further investigate the correlation between irisin and CRP levels.

Methods

We systematically searched PubMed, the Cochrane Library, Web of Science, Embase, SCOPUS, and Ovid to retrieve studies assessing the correlation between irisin and CRP levels. Meta-analyses were performed using a random-effects model, and the I² index was used to evaluate heterogeneity.

Results

Of the 428 studies that were initially found, 14 studies with 2,530 participants met the inclusion criteria for the meta-analysis. The pooled effect size was calculated as 0.052 (95% confidence interval, −0.047 to 0.152; P=0.302). Subgroup analyses identified s ignificant, positive, but weak correlations between CRP and irisin levels in cohort studies, studies conducted among healthy participants, studies in which the male-to-female ratio was less than 1, in overweight or obese subjects, and in studies with a sample size of at least 100 participants.

Conclusion

The present meta-analysis found no overall significant correlation between irisin and CRP levels, although a significant positive correlation was found in overweight or obese subjects. Well-designed studies are needed to verify the results of the present meta-analysis.

Citations

Citations to this article as recorded by

Zinc Supplementation in Individuals with Prediabetes and type 2 Diabetes: a GRADE-Assessed Systematic Review and Dose-Response Meta-analysis
Matin Nazari, Mahlagha Nikbaf-Shandiz, Fereshteh Pashayee-Khamene, Reza Bagheri, Kian Goudarzi, Navid Vahid Hosseinnia, Sina Dolatshahi, Hossein Salehi Omran, Niusha Amirani, Damoon Ashtary-larky, Omid Asbaghi, Matin Ghanavati
Biological Trace Element Research.2024; 202(7): 2966. CrossRef
Irisin reduces inflammatory signaling pathways in inflammation-mediated metabolic syndrome
John J. Slate-Romano, Naohiro Yano, Ting C. Zhao
Molecular and Cellular Endocrinology.2022; 552: 111676. CrossRef
Circulating Irisin Levels in Patients with Chronic Plaque Psoriasis
Francesca Ambrogio, Lorenzo Sanesi, Angela Oranger, Chiara Barlusconi, Manuela Dicarlo, Patrizia Pignataro, Roberta Zerlotin, Paolo Romita, Elvira Favoino, Gerardo Cazzato, Nicoletta Cassano, Gino Antonio Vena, Caterina Foti, Maria Grano
Biomolecules.2022; 12(8): 1096. CrossRef
Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target
Xin Zhang, Can Hu, Hai-ming Wu, Zhen-guo Ma, Qi-zhu Tang
Acta Pharmacologica Sinica.2021; 42(9): 1390. CrossRef
Progress and Challenges in the Biology of FNDC5 and Irisin
Steffen Maak, Frode Norheim, Christian A Drevon, Harold P Erickson
Endocrine Reviews.2021; 42(4): 436. CrossRef
L-arginine supplementation to mitigate cardiovascular effects of walking outside in the context of traffic-related air pollution in participants with elevated blood pressure: A randomized, double-blind, placebo-controlled trial
Hongyu Li, Qisijing Liu, Zhiyong Zou, Qiao Chen, Wanzhou Wang, Andrea A. Baccarelli, Furong Deng, Xinbiao Guo, Shaowei Wu
Environment International.2021; 156: 106631. CrossRef
“Association between dietary inflammatory index (DII) and risk of irritable bowel syndrome: a case-control study”
Elham Eslampour, Koroush Ghanadi, Vahideh Aghamohammadi, Alireza Moayed Kazemi, Rasool Mohammadi, Farhad Vahid, Amir Abbasnezhad
Nutrition Journal.2021;[Epub] CrossRef
Roles and Mechanisms of Irisin in Attenuating Pathological Features of Osteoarthritis
Xiangfen Li, Xiaofang Zhu, Hongle Wu, Thomas E. Van Dyke, Xiaoyang Xu, Elise F. Morgan, Wenyu Fu, Chuanju Liu, Qisheng Tu, Dingming Huang, Jake Chen
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Irisin, interleukin-33 and interleukin-37 in patients with ischemic heart disease and obesity
Yuliia Kovalova, Nataliia Sukhonos, Valeriia Brek, Kateryna Smolianyk
Medicinski casopis.2021; 55(3): 87. CrossRef
Effect of ursodeoxycholic acid therapy due to pregnant intrahepatic cholestasis on chemerin and irisin levels
Krzysztof Dąbrowski, Rafał Kierach, Beniamin O. Grabarek, Dariusz Boroń, Michał Kukla
Dermatologic Therapy.2020;[Epub] CrossRef
The effects of royal jelly and tocotrienol‐rich fraction on impaired glycemic control and inflammation through irisin in obese rats
Pardis Irandoost, Naimeh Mesri Alamdari, Atoosa Saidpour, Farzad Shidfar, Neda Roshanravan, Mohammad Asghari Jafarabadi, Farnaz Farsi, Nazanin Asghari Hanjani, Mohammadreza Vafa
Journal of Food Biochemistry.2020;[Epub] CrossRef
COVID-19: Could Irisin Become the Handyman Myokine of the 21st Century?
Alessia Catalano
Coronaviruses.2020; 1(1): 32. CrossRef
Effect of l-arginine supplementation on C-reactive protein and other inflammatory biomarkers: A systematic review and meta-analysis of randomized controlled trials
Behzad Nazarian, Ezatollah Fazeli Moghadam, Omid Asbaghi, Mohammad Zeinali Khosroshahi, Razieh Choghakhori, Amir Abbasnezhad
Complementary Therapies in Medicine.2019; 47: 102226. CrossRef
The effect of green tea on C-reactive protein and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
Omid Asbaghi, Faezeh Fouladvand, Michael J. Gonzalez, Vahideh Aghamohammadi, Razieh Choghakhori, Amir Abbasnezhad
Complementary Therapies in Medicine.2019; 46: 210. CrossRef

Diabetes
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis: Jae Hyun Bae, Sunhee Kim, Eun-Gee Park, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim; Endocrinol Metab. 2019;34(1):80-92. Published online March 21, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.1.80

8,991 View
296 Download
42 Web of Science
45 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

To investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type 2 diabetes.

Methods

MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized controlled trials (RCTs) of DPP-4 inhibitors from inception to September 2017. We selected eligible RCTs comparing DPP-4 inhibitors with placebo or other antidiabetic agents and reporting at least one renal outcome. A meta-analysis was conducted to calculate standardized mean differences, weighted mean differences (WMDs), relative risks (RRs), and 95% confidence intervals (CIs) for each renal outcome.

Results

We included 23 RCTs with 19 publications involving 41,359 patients. Overall changes in urine albumin-to-creatinine ratio were comparable between DPP-4 inhibitors and controls (P=0.150). However, DPP-4 inhibitors were associated with significantly lower risk of incident microalbuminuria (RR, 0.89; 95% CI, 0.80 to 0.98; P=0.022) and macroalbuminuria (RR, 0.77; 95% CI, 0.61 to 0.97; P=0.027), as well as higher rates of regression of albuminuria (RR, 1.22; 95% CI, 1.10 to 1.35; P<0.001) compared with controls. Although DPP-4 inhibitors were associated with small but significantly lower estimated glomerular filtration rate (WMD, −1.11 mL/min/1.73 m²; 95% CI, −1.78 to −0.44; P=0.001), there was no difference in the risk of end-stage renal disease between two groups (RR, 0.93; 95% CI, 0.76 to 1.14; P=0.475).

Conclusion

DPP-4 inhibitors had beneficial renal effects mainly by reducing the risk of development or progression of albuminuria compared with placebo or other antidiabetic agents.

Citations

Citations to this article as recorded by

Positive impact of DPP-4 or SGLT2 inhibitors on mild cognitive impairment in type 2 diabetes patients on metformin therapy: A metabolomic mechanistic insight
Shams T. Osman, Waziha Purba, Oluwatosin Daramola, Md Mostofa Al Amin Bhuiyan, Judith Nwaiwu, Mojibola Fowowe, Junyao Wang, Noha A. Hamdy, Mahmoud A. Agami, Amr Y. El-Feky, Labiba K. El-Khordagui, Yehia S. Mechref, Ahmed F. El-Yazbi
Biomedicine & Pharmacotherapy.2025; 182: 117771. CrossRef
Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study
Mototsugu Nagao, Jun Sasaki, Kyoko Tanimura-Inagaki, Ichiro Sakuma, Hitoshi Sugihara, Shinichi Oikawa
Cardiovascular Diabetology.2024;[Epub] CrossRef
Repurposing DPP-4 Inhibitors as a Novel Intervention in COVID-19: In Silico Analysis for SARS-CoV-2 Spike Glycoprotein Inhibition
Chhanda Charan Danta, Manoj Kumar Mahapatra
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences.2024; 94(3): 635. CrossRef
Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
Yong Gong, Xueyan Bai, Donglei Zhang, Xingsheng Yang, Zheng Qin, Yu Yang, Yilun Zhou, Jie Meng, Xin Liu
Lipids in Health and Disease.2024;[Epub] CrossRef
Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users
Hideaki Hashimoto, Michihiro Satoh, Shingo Nakayama, Maya Toyama, Takahisa Murakami, Taku Obara, Naoki Nakaya, Takefumi Mori, Atushi Hozawa, Hirohito Metoki
Diabetes, Obesity and Metabolism.2024; 26(10): 4460. CrossRef
Safety and Efficiency of Dipeptidyl Peptidase IV Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis
Adili Tuersun, Munire Mohetaer, Guanxin Hou, Gang Cheng
Current Therapeutic Research.2024; 101: 100763. CrossRef
Transforming Diabetes Care: The Expanding Role of DPP-4 Inhibitors in Cardiovascular and Renal Protection
Francisco Epelde
Medicina.2024; 60(11): 1793. CrossRef
Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i
Emmanouil Korakas, John Thymis, Evangelos Oikonomou, Konstantinos Mourouzis, Aikaterini Kountouri, Loukia Pliouta, Sotirios Pililis, George Pavlidis, Stamatios Lampsas, Konstantinos Katogiannis, Lina Palaiodimou, Georgios Tsivgoulis, Gerasimos Siasos, Ign
Journal of Clinical Medicine.2024; 13(24): 7497. CrossRef
Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events
Edoardo Mannucci, Marco Gallo, Andrea Giaccari, Riccardo Candido, Basilio Pintaudi, Giovanni Targher, Matteo Monami
Diabetes, Obesity and Metabolism.2023; 25(2): 444. CrossRef
Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway
Sarah M. AL-Qabbaa, Samaher I. Qaboli, Tahani K. Alshammari, Maha A. Alamin, Haya M. Alrajeh, Lama A. Almuthnabi, Rana R. Alotaibi, Asma S. Alonazi, Anfal F. Bin Dayel, Nawal M. Alrasheed, Nouf M. Alrasheed
International Journal of Molecular Sciences.2023; 24(7): 6532. CrossRef
Take an individualized and multipronged approach when managing older adults with type 2 diabetes
Sheridan M. Hoy
Drugs & Therapy Perspectives.2023; 39(5): 171. CrossRef
Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh
Endocrine Practice.2023; 29(7): 509. CrossRef
Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
Cheuk To Chung, Ishan Lakhani, Oscar Hou In Chou, Teddy Tai Loy Lee, Edward Christopher Dee, Kenrick Ng, Wing Tak Wong, Tong Liu, Sharen Lee, Qingpeng Zhang, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou
Cancer Medicine.2023; 12(11): 12299. CrossRef
Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes
Deborah J. Wexler, Ian H. de Boer, Alokananda Ghosh, Naji Younes, Ionut Bebu, Silvio E. Inzucchi, Janet B. McGill, Sunder Mudaliar, David Schade, Michael W. Steffes, William V. Tamborlane, Meng H. Tan, Faramarz Ismail-Beigi, Jill P. Crandall, Melissa Dian
JAMA Internal Medicine.2023; 183(7): 705. CrossRef
SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS
M. Ganeva
Trakia Journal of Sciences.2023; 21(1): 54. CrossRef
Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
Christian W. Mende
Advances in Therapy.2022; 39(1): 148. CrossRef
Management of Hyperglycemia in Older Adults with Type 2 Diabetes
Gunjan Y. Gandhi, Arshag D. Mooradian
Drugs & Aging.2022; 39(1): 39. CrossRef
Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
Zhen Ruan, Huimin Zou, Qing Lei, Carolina Oi Lam Ung, Honghao Shi, Hao Hu
Expert Review of Pharmacoeconomics & Outcomes Research.2022; 22(4): 555. CrossRef
Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
Hiroki Teragawa, Takeshi Morimoto, Yuichi Fujii, Tomohiro Ueda, Mio Sakuma, Michio Shimabukuro, Osamu Arasaki, Koichi Node, Takashi Nomiyama, Shinichiro Ueda
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 685. CrossRef
Glomerular filtration rate as a kidney outcome of diabetic kidney disease: a focus on new antidiabetic drugs
Hyo Jin Kim, Sang Soo Kim, Sang Heon Song
The Korean Journal of Internal Medicine.2022; 37(3): 502. CrossRef
The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus
Wan-Chia Hsu, Chun-Sheng Lin, Jung-Fu Chen, Chih-Min Chang
Journal of Clinical Medicine.2022; 11(9): 2653. CrossRef
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
Hiroaki Yagyu, Hitoshi Shimano
Journal of Diabetes Investigation.2022; 13(9): 1472. CrossRef
Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure
Ayesha Abdul Qadir Memon, Sarmad Iqbal
Global Journal of Medical, Pharmaceutical, and Biomedical Update.2022; 17: 12. CrossRef
The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes
Daniel V. O'Hara, Thomas R. Parkhill, Sunil V. Badve, Min Jun, Meg J. Jardine, Vlado Perkovic
Diabetes, Obesity and Metabolism.2021; 23(3): 763. CrossRef
Urinary DPP4 correlates with renal dysfunction, and DPP4 inhibition protects against the reduction in megalin and podocin expression in experimental CKD
Acaris Benetti, Flavia Letícia Martins, Letícia Barros Sene, Maria Heloisa M. Shimizu, Antonio C. Seguro, Weverton M. Luchi, Adriana C. C. Girardi
American Journal of Physiology-Renal Physiology.2021; 320(3): F285. CrossRef
Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
Johannes F.E. Mann, Marcel H.A. Muskiet
Kidney International.2021; 99(2): 314. CrossRef
Renoprotective Effects of DPP-4 Inhibitors
Daiji Kawanami, Yuichi Takashi, Hiroyuki Takahashi, Ryoko Motonaga, Makito Tanabe
Antioxidants.2021; 10(2): 246. CrossRef
Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney
Paul E. Squires, Gareth W. Price, Ulrik Mouritzen, Joe A. Potter, Bethany M. Williams, Claire E. Hills
International Journal of Molecular Sciences.2021; 22(6): 2809. CrossRef
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Endocrinology and Metabolism.2021; 36(2): 388. CrossRef
Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
Jack Wei Chieh Tan, David Sim, Junya Ako, Wael Almahmeed, Mark E Cooper, Jamshed J Dalal, Chaicharn Deerochanawong, David Wei Chun Huang, Sofian Johar, Upendra Kaul, Sin Gon Kim, Natalie Koh, Alice Pik-Shan Kong, Rungroj Krittayaphong, Bernard Kwok, Bien
European Cardiology Review.2021;[Epub] CrossRef
Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists
Francesco Prattichizzo, Paola de Candia, Antonio Ceriello
Metabolism.2021; 120: 154799. CrossRef
SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
Robert C. Stanton
Seminars in Nephrology.2021; 41(2): 85. CrossRef
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Nina Vodošek Hojs, Sebastjan Bevc, Robert Ekart, Nejc Piko, Tadej Petreski, Radovan Hojs
Pharmaceuticals.2021; 14(6): 561. CrossRef
Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus
Swayam Prakash Srivastava, Han Zhou, Ocean Setia, Alan Dardik, Carlos Fernandez‐Hernando, Julie Goodwin
Journal of the American Heart Association.2021;[Epub] CrossRef
Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
Swayam Prakash Srivastava, Rohit Srivastava, Subhash Chand, Julie E. Goodwin
Pharmaceuticals.2021; 14(8): 751. CrossRef
Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: A systematic review and meta-analysis
SaikatK Dalui, Raja Chakraverty, Nafisha Yasmin, Smita Pattanaik, Kaushik Pandit, Suparna Chatterjee
Indian Journal of Endocrinology and Metabolism.2021; 25(4): 283. CrossRef
Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
Yueh-Ting Lee, Chien-Ning Hsu, Chung-Ming Fu, Shih-Wei Wang, Chiang-Chi Huang, Lung-Chih Li
Frontiers in Pharmacology.2021;[Epub] CrossRef
The Role of DPP-4 Inhibitors in Type-2 Diabetes Patients with Chronic Kidney Disease
Mishal Yousef Alqurashi, Khalid Faisal Alharthi, Abdulaziz Abdulrahman Alshehri, Yazeed Khalid Alharbi, Mohammad Abdulmunem Sanousi, Anas Abdullah Almazyed, Khulud Saeed Alghamdi, Sarah Musaad Alrashidi, Waad Abdullah Qaeed, Amjad Aedh Alasmari
Pharmacophore.2021; 12(3): 91. CrossRef
Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
Zoi Kleinaki, Stella Kapnisi, Sofia-Andriani Theodorelou-Charitou, Ilias P. Nikas, Stavroula A. Paschou
Hormones.2020; 19(4): 467. CrossRef
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy.2020; 11(2): 369. CrossRef
Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang, Edward Chia-Cheng Lai
Cardiovascular Diabetology.2020;[Epub] CrossRef
Novel therapeutic agents for the treatment of diabetic kidney disease
Rachel E. Hartman, P.S.S. Rao, Mariann D. Churchwell, Susan J. Lewis
Expert Opinion on Investigational Drugs.2020; 29(11): 1277. CrossRef
Renal protection with glucagon-like peptide-1 receptor agonists
Martina Vitale, Jonida Haxhi, Tiziana Cirrito, Giuseppe Pugliese
Current Opinion in Pharmacology.2020; 54: 91. CrossRef
Loss of Mitochondrial Control Impacts Renal Health
Swayam Prakash Srivastava, Keizo Kanasaki, Julie E. Goodwin
Frontiers in Pharmacology.2020;[Epub] CrossRef
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
Scientific Reports.2019;[Epub] CrossRef

First
Prev
Page of 1
Next
Last

Search